<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003393" GROUP_ID="PREG" ID="133600030114263254" MERGED_FROM="" MODIFIED="2008-08-13 14:33:01 +0200" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Notes for reviewers:&lt;br&gt;1. Please ensure that you are familiar with the generic protocol before starting on your review.&lt;br&gt;2. Please complete the background and modify the rest of the text to be relevant to this review.&lt;br&gt;3. Data extraction from the original trial reports will be done centrally, and you will be supplied with copies of the trials and the completed data extraction forms between the end of March and mid-April.&lt;br&gt;4. Please check that you are happy with the data extraction, and contact authors of trial reports for any clarification needed.&lt;br&gt;5. Please enter the data into the tables, which have already been constructed in this template. &lt;br&gt;6. Please note that you should only include those outcomes with data in the analysis tables as described in the generic protocol.&lt;br&gt;7. After completing the analysis, complete the text of the review and the abstract.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-08-13 13:29:22 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0134" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-08-13 14:33:01 +0200" MODIFIED_BY="Sonja Henderson">
<TITLE>Oestrogens alone or with amniotomy for cervical ripening or induction of labour</TITLE>
<CONTACT MODIFIED="2008-08-13 14:33:01 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="16038" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jane</FIRST_NAME><LAST_NAME>Thomas</LAST_NAME><EMAIL_1>jane_thomas@onetel.com</EMAIL_1><ADDRESS><DEPARTMENT>C/o Cochrane Pregnancy and Childbirth Group, School of Reproductive and Developmental Medicine, Division of Perinatal and Reproductive Medicine</DEPARTMENT><ORGANISATION>The University of Liverpool</ORGANISATION><ADDRESS_1>First Floor, Liverpool Women's NHS Foundation Trust</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 7024066</PHONE_1><FAX_1>+44 151 7024335</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-08-13 14:33:01 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="16038" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jane</FIRST_NAME><LAST_NAME>Thomas</LAST_NAME><EMAIL_1>jane_thomas@onetel.com</EMAIL_1><ADDRESS><DEPARTMENT>C/o Cochrane Pregnancy and Childbirth Group, School of Reproductive and Developmental Medicine, Division of Perinatal and Reproductive Medicine</DEPARTMENT><ORGANISATION>The University of Liverpool</ORGANISATION><ADDRESS_1>First Floor, Liverpool Women's NHS Foundation Trust</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 7024066</PHONE_1><FAX_1>+44 151 7024335</FAX_1></ADDRESS></PERSON><PERSON ID="15928" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Anthony</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Kelly</LAST_NAME><POSITION>Consultant Obstetrician and Gynaecologist</POSITION><EMAIL_1>tony.kelly@bsuh.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>Brighton and Sussex University Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Royal Sussex County Hospital</ADDRESS_1><ADDRESS_2>Eastern Road</ADDRESS_2><CITY>Brighton</CITY><ZIP>BN2 5BE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1273 696955</PHONE_1></ADDRESS></PERSON><PERSON ID="12927" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Josephine</FIRST_NAME><LAST_NAME>Kavanagh</LAST_NAME><POSITION>Research Officer</POSITION><EMAIL_1>j.kavanagh@ioe.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Evidence for Policy and Practice Information and Co-ordinating Centre</DEPARTMENT><ORGANISATION>Social Science Research Unit</ORGANISATION><ADDRESS_1>Institute of Education, University of London</ADDRESS_1><ADDRESS_2>18 Woburn Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1H 0NR</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 76126389</PHONE_1><FAX_1>+44 20 76126400</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-08-12 16:18:07 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 17/04/08&lt;/p&gt;&lt;p&gt;New studies sought but none found: 20/01/08&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 20/01/08&lt;/p&gt;" NOTES_MODIFIED="2008-08-12 16:18:07 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="17" MONTH="4" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="1" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="10" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2008-08-12 16:19:26 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Four new studies were identified evaluated for the purpose of this update.( Griffin 2003, Larmon 2002, Moran 1994, Theiry 1979)  One of these (Larmon 2002) is inlcuded in the review, the other three excluded, two because they did not report any of the prespecified outcomes (Griffin 2003, Moran 1994) and  one (Theiry 1979)  becasue it was a a &amp;quot;complex intervention&amp;quot; the oestrogen used within the trial was combined with the use of an extra amniotic placed foley catheter. A study awaiting awaiting assessment  in the previous review has now been excluded (Luther 1980) again because the trail evaluated a &amp;quot;complex  intervention&amp;quot; of intramuscular oestrdiol  with PGE2.&lt;/p&gt;" NOTES_MODIFIED="2008-08-12 16:19:26 +0100" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-08-04 16:43:38 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-12 16:19:26 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Four new studies were identified and evaluated for the purpose of this update (<LINK REF="STD-Griffin-2003" TYPE="STUDY">Griffin 2003</LINK>; <LINK REF="STD-Larmon-2002" TYPE="STUDY">Larmon 2002</LINK>; <LINK REF="STD-Moran-1994" TYPE="STUDY">Moran 1994</LINK>; <LINK REF="STD-Thiery-1979" TYPE="STUDY">Thiery 1979</LINK>). One of these (<LINK REF="STD-Larmon-2002" TYPE="STUDY">Larmon 2002</LINK>) is included in the review; the other three excluded: two because they did not report any of the prespecified outcomes (<LINK REF="STD-Griffin-2003" TYPE="STUDY">Griffin 2003</LINK>; <LINK REF="STD-Moran-1994" TYPE="STUDY">Moran 1994</LINK>) and one (<LINK REF="STD-Thiery-1979" TYPE="STUDY">Thiery 1979</LINK>) because it was a "complex intervention" - the oestrogen used within the trial was combined with the use of an extra amniotic placed foley catheter. A study awaiting awaiting assessment in the previous review has now been excluded (<LINK REF="STD-Luther-1980" TYPE="STUDY">Luther 1980</LINK>), again because the trial evaluated a "complex intervention" of intramuscular oestradiol with PGE2.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-08-04 16:44:06 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-13 13:29:22 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-08-12 16:08:40 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-08-12 15:22:55 +0100" MODIFIED_BY="[Empty name]">Oestrogens alone or with amniotomy for cervical ripening or induction of labour</TITLE>
<SUMMARY_BODY MODIFIED="2008-08-12 16:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>There is not enough evidence, from randomised controlled trials, to show the effects and safety of oestrogen to ripen the cervix and help bring on labour. </P>
<P>Sometimes it is necessary to bring on labour artificially, because of safety concerns for either the pregnant woman or baby. Oestrogen is a hormone involved in the ripening of the neck of the womb (cervix) and preparing it for the birth of the baby. It is possible that oestrogen increases the release of other local hormones (prostaglandins) which help ripen the cervix. A variety of oestrogen preparations have been used (such as tablets, creams and infusions). They have been used for inductions when women are inpatients and outpatients. There is not enough research from the review of seven studies (with 465 women) to show the true effect of oestrogen. Oestrogen is not commonly used in current clinical practice as alternative agents that are known to be effective are available.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-13 13:29:22 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-08-13 13:14:56 +0100" MODIFIED_BY="[Empty name]">
<P>It is suggested that oestrogen may promote changes in cervical favourability with minimal effect on uterine activity and could be used to induce labour or prime the cervix. A variety of oestrogen preparations (infusions, gels, creams and tablets) and routes of administrations (oral, vaginal, extra-amniotic) vaginal,extra-amniotic) have been used in inpatient and outpatient settings. Oestrogen is rarely used in clinical practice. There are no commercially available preparations of oestrogen for induction and in most cases this is prepared specifically for the study.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-08-12 11:26:53 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness and safety of oestrogens alone, or with amniotomy, for third trimester cervical ripening and induction of labour in comparison with other methods of induction of labour.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Pregnancy and Childbirth Group trials register (January 2008), the Cochrane Register of Controlled Trials (<I>The Cochrane Library,</I> Issue 4, 2007), and bibliographies of relevant papers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials comparing oestrogens for third trimester cervical ripening or labour induction with placebo/no treatment or other methods listed above it on a predefined list of labour induction methods.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-08-13 13:17:49 +0100" MODIFIED_BY="[Empty name]">
<P>Studies were assessed by at least two review authors. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-08-13 13:29:22 +0100" MODIFIED_BY="[Empty name]">
<P>Seven studies (465 women) were included. Only studies using oestrogens alone were identified; there were no trials of oestrogen with amniotomy. Three studies used intravaginal oestrogen, two used extra-amniotic oestrogen, one used an intravenous preparation, and one used oral tablets. Three studies were inpatient studies, one was an outpatient intervention and three did not state whether the setting was inpatient or outpatient. None of the studies reported the primary outcomes of rates of vaginal delivery not achieved in 24 hours. There were insufficient data to make any meaningful conclusions when comparing oestrogen with vaginal prostaglandin (PGE2), oxytocin alone, or extra amniotic PGF2a, as to whether oestrogen is effective in inducing labour.</P>
<P>There was no evidence of a difference between oestrogen and placebo in the rate of caesarean section, uterine hyperstimulation with or without fetal heart rate changes, or instrumental vaginal delivery.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-08-13 13:23:02 +0100" MODIFIED_BY="[Empty name]">
<P>There were insufficient data to quantify the safety and effectiveness of oestrogen as an induction agent; they should only be used as part of randomised control trials as there are alternative effective options for inducting labour.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-12 16:36:54 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-08-12 16:05:10 +0100" MODIFIED_BY="[Empty name]">
<P>Sometimes it is necessary to bring on labour artificially because of safety concerns for the mother or baby. This review is one of a series of reviews of methods of labour induction using a standardised protocol. For more detailed information on the rationale for this methodological approach, please refer to the currently published 'generic' protocol (<LINK REF="REF-Hofmeyr-2000" TYPE="REFERENCE">Hofmeyr 2000</LINK>). The generic protocol describes how a number of standardised reviews will be combined to compare various methods of preparing the cervix of the uterus and inducing labour.</P>
<P>Studies in sheep showed that there is a pre-labour rise in oestrogen and a decrease in progesterone, both of these changes stimulate prostaglandin production and may help initiate labour. Research in humans has failed to demonstrate a similar physiological mechanism. However oestrogen has been suggested as an effective cervical ripening and induction agent, promoting changes in cervical favourability but with less effect on uterine activity and as such could be used to induce labour, or prime the cervix and uterus, prior to induction with other methods. There has been a slight resurgence of interest in oestrogens as an agent for cervical ripening in an outpatient setting, and induction of labour in outpatient versus inpatient settings are the subject of another review (<LINK REF="REF-Kelly-2008" TYPE="REFERENCE">Kelly 2008</LINK>). Most studies have used natural oestrogen analogues such as oestradiol. More potent synthetic oestrogens such as stilbestrol are no longer used because of the long term adverse events in female children. Oestrogens are associated with a variety of adverse effects (such as an increase in thromboembolic disease) which could reduce the potential benefit of their use in pregnancy. A variety of oestrogen preparations (including tablets, infusions, gels and creams) and routes of administrations have been used (oral, rectal, vaginal, intracervical, extra-amniotic and intravenous routes). Administration of some oestrogen preparations such as tablets gels or creams will be possible in either an inpatient or outpatient setting. However, using intravenous or extraamniotic infusions are likely to only be possible in an inpatient setting. In most studies the oestrogen was prepared specifically for the study. The use of oestrogen as an induction agent is not currently in common use in clinical practice and there are no commercially available preparations of oestrogen for its use in cervical ripening or induction of labour .<BR/>
</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-08-12 11:57:43 +0100" MODIFIED_BY="[Empty name]">
<P>To determine, from the best available evidence, the effectiveness and safety of oestrogens alone, or with amniotomy, for third trimester cervical ripening and induction of labour in comparison with other methods of induction of labour.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-12 16:36:54 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-08-12 15:29:52 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-08-12 15:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical trials comparing oestrogens alone or with amniotomy for cervical ripening or labour induction, with placebo/no treatment or other methods listed above it on a predefined list of methods of labour induction (see '<LINK TAG="DATA_COLLECTION" TYPE="SECTION">Data collection and analysis</LINK>'); the trials included some form of random allocation to either group; and they reported one or more of the prestated outcomes.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-08-12 15:29:52 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant women due for third trimester induction of labour, carrying a single live fetus. Women having induction of labour in either inpatient or outpatient settings will be included.</P>
<P>Predefined sub-group analyses will be (see <LINK TAG="DATA_COLLECTION" TYPE="SECTION">Data collection and analysis</LINK>): previous caesarean section or not; nulliparity or multiparity; membranes intact or ruptured, and cervix unfavourable, favourable or undefined. Only those outcomes with data will appear in the analysis tables.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-08-12 15:24:34 +0100" MODIFIED_BY="[Empty name]">
<P>There are a variety of oestrogen preparations (tablets, infusions, gels and creams) and several possible routes of administrations have been used (oral, rectal, vaginal, intracervical, extra-amniotic and intravenous routes). We will include any oestrogen used alone or with amniotomy compared with any of the 14 interventions listed above oestrogen in the generic protocol (namely: 1. placebo/no treatment; 2. vaginal prostaglandins; 3. intracervical prostaglandins; 4.intravenous oxytocin; 5.amniotomy; 6.intravenous oxytocin with amniotomy; 7. vaginal misoprostol; 8.oral misoprostol; 9.mechanical methods including extra-amniotic Foley catheter; 10.membrane sweeping; 11.extra-amniotic prostaglandins; 12.intravenous prostaglandins; 13.oral prostaglandins; and 14 mifepristone).</P>
<P>As a number of trials administer oestrogen via a Foley catheter into the extra amniotic space, it was decided by the authors prior to data extraction to exclude any trial where the Foley catheter balloon was inflated to any volume greater than or equal to 10 mls. At this level it was felt that there was potential for the catheter balloon to have an additional effect to the oestrogens, and that this interaction would make it difficult to measure the effect of oestrogens.</P>
<P>For oestrogen and amniotomy to be considered as concomitant interventions both needed to be delivered within two hours of each other. This is in accordance with other reviews on induction of labour where amniotomy is considered as a concomitant intervention. Studies of oestrogen and amniotomy with other interventions are considered separate comparisons.</P>
<P>It is possible to use some oestrogen preparations (such as tablets, gels or creams) by oral or vaginal route in either inpatient or outpatient settings. However, using intravenous or extraamniotic infusion are likely to only be possible in an inpatient setting.</P>
<P>The primary comparisons listed below are the only comparisons for which there are data. Comparisons for which no studies were identified (namely oestrogens with amniotomy and comparison with vaginal misoprostol; oral misoprostol; mechanical methods including extra-amniotic Foley catheter; membrane sweeping; intravenous prostaglandins; oral prostaglandins; and mifepristone) are not listed below.</P>
<P>Primary comparisons.<BR/>(1) oestrogen alone (all routes) versus placebo (all routes);<BR/>(2) oestrogen alone (all routes) versus vaginal prostaglandin;<BR/>(3) oestrogen alone (all routes) versus intracervical prostaglandin;<BR/>(4) oestrogen alone (all routes) versus oxytocin alone;<BR/>(5) oestrogen alone (all routes) versus extra-amniotic prostaglandins.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-12 12:22:23 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically relevant outcomes for trials of methods of cervical ripening/labour induction have been prespecified by two authors of labour induction reviews (Justus Hofmeyr and Zarko Alfirevic). Differences were settled by discussion.</P>
<P>Five primary outcomes were chosen as being most representative of the clinically important measures of effectiveness and complications. Sub-group analyses will be limited to the primary outcomes:<BR/>(1) vaginal delivery not achieved within 24 hours;<BR/>(2) uterine hyperstimulation with fetal heart rate (FHR) changes;<BR/>(3) caesarean section;<BR/>(4) serious neonatal morbidity or perinatal death (e.g. seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood);<BR/>(5) serious maternal morbidity or death (e.g. uterine rupture, admission to intensive care unit, septicaemia).</P>
<P>Perinatal and maternal morbidity and mortality are composite outcomes. This is not an ideal solution because some components are clearly less severe than others. It is possible for one intervention to cause more deaths but less severe morbidity. However, in the context of labour induction at term this is unlikely. All these events will be rare, and a modest change in their incidence will be easier to detect if composite outcomes are presented. The incidence of individual components will be explored as secondary outcomes (see below).</P>
<P>Secondary outcomes relate to measures of effectiveness, complications and satisfaction:</P>
<P>Measures of effectiveness:<BR/>(6) cervix unfavourable/unchanged after 12 to 24 hours;<BR/>(7) oxytocin augmentation.</P>
<P>Complications:<BR/>(8) uterine hyperstimulation without FHR changes;<BR/>(9) uterine rupture;<BR/>(10) epidural analgesia;<BR/>(11) instrumental vaginal delivery;<BR/>(12) meconium stained liquor;<BR/>(13) Apgar score &lt; 7 at 5 minutes;<BR/>(14) neonatal intensive care unit admission;<BR/>(15) neonatal encephalopathy;<BR/>(16) perinatal death;<BR/>(17) disability in childhood;<BR/>(18) maternal side effects (all);<BR/>(19) maternal nausea;<BR/>(20) maternal vomiting;<BR/>(21) maternal diarrhoea;<BR/>(22) other maternal side-effects (e.g. thromboembolic events);<BR/>(23) postpartum haemorrhage (as defined by the trial authors);<BR/>(24) serious maternal complications (e.g. intensive care unit admission, septicaemia but excluding uterine rupture);<BR/>(25) maternal death.</P>
<P>Measures of satisfaction:<BR/>(26) woman not satisfied;<BR/>(27) caregiver not satisfied.</P>
<P>While all the above outcomes were sought, only those with data appear in the analysis tables.</P>
<P>The aim of treatment maybe either cervical ripening and/or induction of labour. Where the aim of treatment is cervical ripening for example in an outpatient setting rather than induction of labour, then the other primary outcomes rather than "vaginal delivery not achieved within 24 hours" are more relevant.</P>
<P>The terminology of uterine hyperstimulation is problematic (<LINK REF="REF-Curtis-1987" TYPE="REFERENCE">Curtis 1987</LINK>). In the review we used the term 'uterine hyperstimulation without FHR changes' to include uterine tachysystole (&gt; 5 contractions per 10 minutes for at least 20 minutes) and uterine hypersystole/hypertonus (a contraction lasting at least two minutes) and 'uterine hyperstimulation with FHR changes' to denote uterine hyperstimulation syndrome (tachysystole or hypersystole with fetal heart rate changes such as persistent decelerations, tachycardia or decreased short term variability).</P>
<P>Outcomes were included in the analysis: if reasonable measures were taken to minimise observer bias; and data were available for analysis according to original allocation.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-12 15:39:00 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group trials register by contacting the Trials Search Co-ordinator (January 2008).</P>
<P>The Cochrane Pregnancy and Childbirth Group's trials register is maintained by the Trials Search Co-ordinator and contains trials identified from:<BR/>1. quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);<BR/>2. monthly searches of MEDLINE;<BR/>3. handsearches of 30 journals and the proceedings of major conferences;<BR/>4. weekly current awareness search of a further 37 journals.</P>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Search strategies for identification of studies' section within the editorial information about the Cochrane Pregnancy and Childbirth Group.</P>
<P>Trials identified through the searching activities described above are given a code (or codes) depending on the topic. The codes are linked to review topics. The Trials Search Co-ordinator searches the register for each review using these codes rather than keywords.</P>
<P>We did not apply any language restrictions. </P>
<P>The initial search was performed simultaneously for all reviews of methods of inducing labour, as outlined in the generic protocol for these reviews (<LINK REF="REF-Hofmeyr-2000" TYPE="REFERENCE">Hofmeyr 2000</LINK>).</P>
<P>The reference lists of trial reports and reviews were searched by hand.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-12 16:36:54 +0100" MODIFIED_BY="[Empty name]">
<P>A strategy has been developed to deal with the large volume and complexity of trial data relating to labour induction. Many methods have been studied, examining the effects of these methods when induction of labour was undertaken in a variety of clinical groups e.g. restricted to primiparous women or those with ruptured membranes. Most trials are intervention-driven, comparing two or more methods in various categories of women. Clinicians and parents need the data arranged according to the clinical characteristics of the women undergoing induction of labour, to be able to choose which method is best for a particular clinical scenario. To extract these data from several hundred trial reports in a single step would be very difficult. We developed a two-stage method of data extraction. The initial data extraction was done in a series of primary reviews arranged by methods of induction of labour, following a standardised methodology. The data was then extracted from the primary reviews into a series of secondary reviews, arranged by the clinical characteristics of the women undergoing induction of labour.</P>
<P>To avoid duplication of data in the primary reviews, the labour induction methods have been listed in a specific order, from one to 23. Each primary review included comparisons between one of the methods (from two to 23) with only those methods above it on the list. Thus, the review of intravenous oxytocin (4) will include only comparisons with intracervical prostaglandins (3), vaginal prostaglandins (2) or placebo (1). Methods identified in the future will be added to the end of the list. The current list is as follows:</P>
<P>(1) placebo/no treatment;<BR/>(2) vaginal prostaglandins (<LINK REF="REF-Kelly-2003" TYPE="REFERENCE">Kelly 2003</LINK>);<BR/>(3) intracervical prostaglandins (<LINK REF="REF-Boulvain-2008" TYPE="REFERENCE">Boulvain 2008</LINK>);<BR/>(4) intravenous oxytocin (<LINK REF="REF-Kelly-2001" TYPE="REFERENCE">Kelly 2001</LINK>);<BR/>(5) amniotomy (<LINK REF="REF-Bricker-2000" TYPE="REFERENCE">Bricker 2000</LINK>);<BR/>(6) intravenous oxytocin with amniotomy (<LINK REF="REF-Howarth-2001" TYPE="REFERENCE">Howarth 2001</LINK>);<BR/>(7) vaginal misoprostol (<LINK REF="REF-Hofmeyr-2003" TYPE="REFERENCE">Hofmeyr 2003</LINK>);<BR/>(8) oral misoprostol (<LINK REF="REF-Alfirevic-2006" TYPE="REFERENCE">Alfirevic 2006</LINK>);<BR/>(9) mechanical methods including extra-amniotic Foley catheter (<LINK REF="REF-Boulvain-2001" TYPE="REFERENCE">Boulvain 2001</LINK>);<BR/>(10) membrane sweeping (<LINK REF="REF-Boulvain-2005" TYPE="REFERENCE">Boulvain 2005</LINK>);<BR/>(11) extra-amniotic prostaglandins (<LINK REF="REF-Hutton-2001" TYPE="REFERENCE">Hutton 2001</LINK>);<BR/>(12) intravenous prostaglandins (<LINK REF="REF-Luckas-2000" TYPE="REFERENCE">Luckas 2000</LINK>);<BR/>(13) oral prostaglandins (<LINK REF="REF-French-2001" TYPE="REFERENCE">French 2001</LINK>);<BR/>(14) mifepristone (<LINK REF="REF-Neilson-2000" TYPE="REFERENCE">Neilson 2000</LINK>);<BR/>(15) oestrogens with or without amniotomy (<LINK REF="REF-Thomas-2001" TYPE="REFERENCE">Thomas 2001</LINK>);<BR/>(16) corticosteroids (<LINK REF="REF-Kavanagh-2006" TYPE="REFERENCE">Kavanagh 2006</LINK>);<BR/>(17) relaxin (<LINK REF="REF-Kelly-2001a" TYPE="REFERENCE">Kelly 2001a</LINK>);<BR/>(18) hyaluronidase <LINK REF="REF-Kavanagh-2006a" TYPE="REFERENCE">Kavanagh 2006a</LINK>;<BR/>(19) castor oil, bath, and/or enema (<LINK REF="REF-Kelly-2001b" TYPE="REFERENCE">Kelly 2001b</LINK>);<BR/>(20) acupuncture (<LINK REF="REF-Smith-2004" TYPE="REFERENCE">Smith 2004</LINK>);<BR/>(21) breast stimulation (<LINK REF="REF-Kavanagh-2005" TYPE="REFERENCE">Kavanagh 2005</LINK>);<BR/>(22) sexual intercourse (<LINK REF="REF-Kavanagh-2001" TYPE="REFERENCE">Kavanagh 2001</LINK>);<BR/>(23) homoeopathic methods (<LINK REF="REF-Smith-2003" TYPE="REFERENCE">Smith 2003</LINK>);<BR/>(24) buccal or sublingual misoprostol (<LINK REF="REF-Muzonzini-2004" TYPE="REFERENCE">Muzonzini 2004</LINK>);</P>
<P>(25) nitric oxide (<LINK REF="REF-Kelly-2008a" TYPE="REFERENCE">Kelly 2008a</LINK>);<BR/>(26) hypnosis.</P>
<P>The primary reviews will be analysed by the following subgroups:<BR/>(1) previous caesarean section or not;<BR/>(2) nulliparity or multiparity;<BR/>(3) membranes intact or ruptured;<BR/>(4) cervix favourable, unfavourable or undefined.</P>
<P>The secondary reviews will include all methods of labour induction for each of the categories of women for which subgroup analysis has been done in the primary reviews, and will include only five primary outcome measures. There will thus be six secondary reviews, of methods of labour induction in the following groups of women:</P>
<P>(1) nulliparous, intact membranes (unfavourable cervix, favourable cervix, cervix not defined);<BR/>(2) nulliparous, ruptured membranes (unfavourable cervix, favourable cervix, cervix not defined);<BR/>(3) multiparous, intact membranes (unfavourable cervix, favourable cervix, cervix not defined);<BR/>(4) multiparous, ruptured membranes (unfavourable cervix, favourable cervix, cervix not defined);<BR/>(5) previous caesarean section (intact or ruptured membranes and unfavourable cervix, favourable cervix, cervix not defined).<BR/>(6) previous caesarean section, ruptured membranes (unfavourable cervix, favourable cervix, cervix not defined).</P>
<P>Each time a primary review is updated with new data, those secondary reviews which include data which have changed, will also be updated.</P>
<P>The trials included in the primary reviews were extracted from an initial set of trials covering all interventions used in induction of labour (see above for details of search strategy). The data extraction process was conducted centrally. This was coordinated from the Clinical Effectiveness Support Unit (CESU) at the Royal College of Obstetricians and Gynaecologists, UK, in co-operation with The Pregnancy and Childbirth Group of The Cochrane Collaboration. This process allowed the data extraction process to be standardised across all the reviews.</P>
<P>The trials were initially reviewed on eligibility criteria, using a standardised form and the basic selection criteria specified above. Following this, data were extracted to a standardised data extraction form which was piloted for consistency and completeness. The pilot process involved the researchers at the CESU and previous reviewers in the area of induction of labour.</P>
<P>Information was extracted regarding the methodological quality of trials on a number of levels. This process was completed without consideration of trial results. Assessment of selection bias examined the process involved in the generation of the random sequence and the method of allocation concealment separately. These were then judged as adequate or inadequate using the criteria described in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for the purpose of the reviews.</P>
<P>Performance bias was examined with regards to whom was blinded in the trials i.e. participant, caregiver, outcome assessor or analyst. In many trials the caregiver, assessor and analyst were the same party. Details of the feasibility and appropriateness of blinding at all levels was sought.</P>
<P>Individual outcome data were included in the analysis if they meet the pre stated criteria in 'Types of outcome measures'. Included trial data were processed as described in the Cochrane Collaboration Handbook (<LINK REF="REF-Cochrane-2008" TYPE="REFERENCE">Cochrane 2008</LINK>). Data extracted from the trials were analysed on an intention to treat basis (when this was not done in the original report, re-analysis is performed if possible). Where data were missing, clarification was sought from the original authors. If the attrition was such that it might significantly affect the results, these data were excluded from the analysis. This decision rested with the reviewers of primary reviews and is clearly documented. If missing data become available, they will be included in the analyses.</P>
<P>Data were extracted from all eligible trials to examine how issues of quality influence effect size in a sensitivity analysis. In trials where reporting was poor, methodological issues were reported as unclear or clarification sought.</P>
<P>Due to the large number of trials, double data extraction was not feasible and agreement between the three data extractors was therefore assessed on a random sample of trials.</P>
<P>Once the data had been extracted, they were distributed to individual reviewers for entry onto the Review Manager computer software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>), checked for accuracy, and analysed as above using the RevMan software. For dichotomous data, relative risks and 95% confidence intervals were calculated, and in the absence of heterogeneity, results were pooled using a fixed-effect model.</P>
<P>The predefined criteria for sensitivity analysis included all aspects of quality assessment as mentioned above, including aspects of selection, performance and attrition bias.</P>
<P>Primary analysis was limited to the prespecified outcomes and sub-group analyses. In the event of differences in unspecified outcomes or sub-groups being found, these were analysed post hoc, but clearly identified as such to avoid drawing unjustified conclusions.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-12 16:09:59 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-08-12 16:04:37 +0100" MODIFIED_BY="[Empty name]">
<P>In total, 25 studies were considered; 18 were excluded and seven (with a total of 465 women) were included. For further details of study characteristics refer to 'characteristics of included/excluded studies'.</P>
<P>All included studies compared oestrogen alone with other interventions, no included studies compared oestrogen with amniotomy with any other interventions.</P>
<UL>
<LI>Excluded studies:</LI>
</UL>
<P>Six studies involved complex interventions, with oestrogen or placebo being combined with an extra amniotic Foley catheter (<LINK REF="STD-Gordon-1977" TYPE="STUDY">Gordon 1977</LINK>; <LINK REF="STD-Peedicayil-1989" TYPE="STUDY">Peedicayil 1989</LINK>; <LINK REF="STD-Pedersen-1981" TYPE="STUDY">Pedersen 1981</LINK>; <LINK REF="STD-Roztocil-1998" TYPE="STUDY">Roztocil 1998</LINK>; <LINK REF="STD-Stewart-1981" TYPE="STUDY">Stewart 1981</LINK>; <LINK REF="STD-Thiery-1979" TYPE="STUDY">Thiery 1979</LINK>). In one study oestrogen or a placebo was then followed by oral prostaglandin E2 (<LINK REF="STD-Luther-1980" TYPE="STUDY">Luther 1980</LINK>).</P>
<P>Eight studies did not report any prespecified outcomes in an extractable format (<LINK REF="STD-Griffin-2003" TYPE="STUDY">Griffin 2003</LINK>; <LINK REF="STD-Klopper-1973" TYPE="STUDY">Klopper 1973</LINK>; <LINK REF="STD-Magnani-1986" TYPE="STUDY">Magnani 1986</LINK>; <LINK REF="STD-Mamo-1994" TYPE="STUDY">Mamo 1994</LINK>; <LINK REF="STD-Moran-1994" TYPE="STUDY">Moran 1994</LINK>; <LINK REF="STD-Palmero-1997" TYPE="STUDY">Palmero 1997</LINK>; <LINK REF="STD-Pedersen-1981" TYPE="STUDY">Pedersen 1981</LINK>; <LINK REF="STD-Thiery-1978" TYPE="STUDY">Thiery 1978</LINK>).</P>
<P>One study involved induction after failed induction (<LINK REF="STD-Martin-1955" TYPE="STUDY">Martin 1955</LINK>).</P>
<P>One study involved intra amniotic administration of oestrogen after the onset of labour (<LINK REF="STD-Klopper-1969" TYPE="STUDY">Klopper 1969</LINK>).</P>
<P>One study involved induction with Dehydroepiandrosterone sulphate (<LINK REF="STD-Sasaki-1982" TYPE="STUDY">Sasaki 1982</LINK>).</P>
<UL>
<LI>Included studies:</LI>
</UL>
<P>The oestrogen preparations used varied. One study (<LINK REF="STD-Klopper-1962" TYPE="STUDY">Klopper 1962</LINK>) used oral tablets, one used intravenous infusion (<LINK REF="STD-Pinto-1967" TYPE="STUDY">Pinto 1967</LINK>), two used extra-amniotic oestrogen (<LINK REF="STD-Peedicayil-1990" TYPE="STUDY">Peedicayil 1990</LINK>, <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>) and three used intravaginal oestrogen cream  (<LINK REF="STD-Larmon-2002" TYPE="STUDY">Larmon 2002</LINK>, <LINK REF="STD-Magann-1995" TYPE="STUDY">Magann 1995</LINK>, <LINK REF="STD-Tromans-1981" TYPE="STUDY">Tromans 1981</LINK>)</P>
<P>
<BR/>Five studies compared oestrogen with placebo. The oestrogen was delivered as oral tablets in one trial (<LINK REF="STD-Klopper-1962" TYPE="STUDY">Klopper 1962</LINK>), as an intravenous infusion in another (<LINK REF="STD-Peedicayil-1990" TYPE="STUDY">Peedicayil 1990</LINK>), as an extra-amniotic formulation in two studies (<LINK REF="STD-Pinto-1967" TYPE="STUDY">Pinto 1967</LINK>; <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>) and a vaginal oestrogen cream in one study (<LINK REF="STD-Larmon-2002" TYPE="STUDY">Larmon 2002</LINK>).
<BR/>

<BR/>One study compared intravaginal oestrogen cream with intravaginal PGE2 (<LINK REF="STD-Tromans-1981" TYPE="STUDY">Tromans 1981</LINK>).</P>
<P>One study compared intravaginal oestrogen cream with intracervical PGE2 (<LINK REF="STD-Larmon-2002" TYPE="STUDY">Larmon 2002</LINK>). Different to other included studies these interventions were given as a weekly outpatient treatment until the onset of spontaneous labour.</P>
<P>One study compared intracervical oestrogen with intracervical PGE2 (<LINK REF="STD-Magann-1995" TYPE="STUDY">Magann 1995</LINK>).</P>
<P>The same study compared intracervical oestrogen with oxytocin (<LINK REF="STD-Magann-1995" TYPE="STUDY">Magann 1995</LINK>).</P>
<P>One study compared extra-amniotic oestrogen with extra-amniotic PGF2a (<LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>).</P>
<P>Three studies had three arms and hence reported in two comparisons (<LINK REF="STD-Magann-1995" TYPE="STUDY">Magann 1995</LINK>; <LINK REF="STD-Larmon-2002" TYPE="STUDY">Larmon 2002</LINK>; <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>).</P>
<P>Three studies (<LINK REF="STD-Pinto-1967" TYPE="STUDY">Pinto 1967</LINK>; <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>,<LINK REF="STD-Tromans-1981" TYPE="STUDY">Tromans 1981</LINK> that included a total of 185 women) stated they were undertaken in an inpatient setting, the first two of these studies used extra-amniotic formulation the third used intravaginal cream. One study using intravaginal cream in the intervention arm (<LINK REF="STD-Larmon-2002" TYPE="STUDY">Larmon 2002</LINK> with 87 women) was undertaken in an outpatient setting. Three studies did not state if the study had been conducted in an inpatient or outpatient setting, the first used oral oestradiol tablets (<LINK REF="STD-Klopper-1962" TYPE="STUDY">Klopper 1962</LINK>), the second (<LINK REF="STD-Magann-1995" TYPE="STUDY">Magann 1995</LINK>) used vaginal cream, and the third (<LINK REF="STD-Peedicayil-1990" TYPE="STUDY">Peedicayil 1990</LINK>) used extra-amniotic oestrogen.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-08-12 16:09:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Randomisation and concealment</LI>
</UL>
<P>One trial used computer-generated random number sequences (<LINK REF="STD-Magann-1995" TYPE="STUDY">Magann 1995</LINK>), one trial used random number tables (<LINK REF="STD-Larmon-2002" TYPE="STUDY">Larmon 2002</LINK>), one trial allocated depending on the date of admission (<LINK REF="STD-Tromans-1981" TYPE="STUDY">Tromans 1981</LINK>) and one trial used alternation as a means of allocation (<LINK REF="STD-Pinto-1967" TYPE="STUDY">Pinto 1967</LINK>). The remaining studies were unclear regarding the method of generation of the randomisation sequence.</P>
<P>Concealment was achieved by sealed opaque envelopes in one trial (<LINK REF="STD-Magann-1995" TYPE="STUDY">Magann 1995</LINK>), opaque numbered envelopes in another (<LINK REF="STD-Larmon-2002" TYPE="STUDY">Larmon 2002</LINK>) and using coded drug boxes or bottles in two further trials (<LINK REF="STD-Peedicayil-1990" TYPE="STUDY">Peedicayil 1990</LINK>; <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>). The remaining studies were unclear regarding concealment or used open allocation as a result of inadequate randomisation methods.</P>
<UL>
<LI>Blinding</LI>
</UL>
<P>Double blinding was accomplished in all four placebo controlled trials (<LINK REF="STD-Klopper-1962" TYPE="STUDY">Klopper 1962</LINK>; <LINK REF="STD-Peedicayil-1990" TYPE="STUDY">Peedicayil 1990</LINK>; <LINK REF="STD-Pinto-1967" TYPE="STUDY">Pinto 1967</LINK>; <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>), and was not possible in the remaining trials due to the nature of the active comparison.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-12 12:49:48 +0100" MODIFIED_BY="[Empty name]">
<P>None of the studies compared oestrogen with amniotomy. None of the studies reported the primary outcome of rates of either vaginal delivery not achieved in 24 hours, or the measure of effectiveness of the cervix unfavourable/unchanged after 12 to 24 hours. There were insufficient data to make any meaningful conclusions when comparing oestrogen with vaginal PGE2, intracervical PGE2, oxytocin alone or extra amniotic PGF2a, as to whether oestrogen is effective for inducing labour.</P>
<P>All the outcomes listed under 'Types of outcome measures' and sub-groups defined in 'Types of participants' were sought. Only those with data appear in the analysis tables.<BR/>Data discussed applies to the 'all women' group and unless stated there was no difference between any of the prespecified sub-groups.</P>
<P>(1) Oestrogen alone (all routes) versus placebo (all routes) (five studies: 306 women)</P>
<P>There was no evidence of a difference between the rate of caesarean section between oestrogen and placebo (14.7% versus 14.6%, relative risk (RR) 1.00, 95% confidence interval (CI) 0.6 to 1.68). There was no evidence of a difference between rates of uterine hyperstimulation with or without fetal heart rate changes or instrumental vaginal delivery.</P>
<P>(2) Oestrogen alone (all routes) versus vaginal prostaglandin (one study: 60 women)</P>
<P>There were insufficient data to make any meaningful conclusions when comparing oestrogen with vaginal PGE2.</P>
<P>(3) Oestrogen alone (all routes) versus intracervical prostaglandin (two studies: 151 women)</P>
<P>There was no evidence of a difference between the rate of caesarean section between oestrogen and intracervical PGE2 (44.1% versus 33.8%, RR 1.33, 95% CI 0.90 to 1.95).There were insufficient data to make any meaningful conclusions when comparing oestrogen with intracervical PGE2.</P>
<P>(4) Oestrogen alone (all routes) versus oxytocin alone (one study: 66 women)</P>
<P>There were insufficient data to make any meaningful conclusions when comparing oestrogen with oxytocin alone.</P>
<P>(5) Oestrogen alone (all routes) versus extra amniotic prostaglandins (one study: 30 women)</P>
<P>There were insufficient data to make any meaningful conclusions when comparing oestrogen with extra amniotic PGF2a.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-12 16:11:43 +0100" MODIFIED_BY="[Empty name]">
<P>There were insufficient data to draw any conclusions regarding the efficacy of oestrogen alone as an induction agent. No trails considered the use of oestrogen with amniotomy and none of the included trials reported on vaginal delivery not achieved within 24 hours.</P>
<P>The delivery of oestrogen within the included trials is varied (oral, intravenous, vaginal, and extra-amniotic), and no attempt was made to sub-divide the routes of administration. The effect of different delivery methods would not be possible to quantify unless much larger numbers of trials were available. In most studies it is specified that the oestrogen preparation was made specifically for the study and was not from a commercially available form. There is very limited information about the use of oestrogens in an outpatient setting. In this context the aim of treatment has been to promote cervical ripening rather than induce labour, and the outcome of achieving a delivery within 24 hours is not the most relevant outcome.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE MODIFIED="2008-07-02 12:48:34 +0100" MODIFIED_BY="[Empty name]">
<P>Oestrogens should not currently be used for induction of labour or cervical ripening as their effectiveness and safety cannot be quantified at present and there are alternative effective treatment options.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-07-02 12:48:46 +0100" MODIFIED_BY="[Empty name]">
<P>Future studies evaluating the effectiveness of oestrogen need to be of good methodological quality and should report on all the outcomes listed in the generic protocol of the induction of labour reviews.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-08-11 16:35:58 +0100" MODIFIED_BY="[Empty name]">
<P>Thanks to Sonja Henderson, Lynn Hampson and Claire Winterbottom for their support in the production of this review. As part of the pre-publication editorial process, this review has been commented on by three peers (an editor and two referees who are external to the editorial team), one or more members of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.</P>
<P>Also thanks to Zarko Alfirevic, Justus Hofmeyr and Jim Neilson. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-11 16:36:34 +0100" MODIFIED_BY="[Empty name]">
<P>J Thomas, AJ Kelly and J Kavanagh were involved in developing the protocol, data extraction, assessment of the trials and drafting and re-drafting the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-12 16:37:07 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Klopper-1962" NAME="Klopper 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klopper AI, Dennis KJ</AU>
<TI>Effect of oestrogens on myometrial contractions</TI>
<SO>BMJ</SO>
<YR>1962</YR>
<VL>2</VL>
<PG>1157-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larmon-2002" NAME="Larmon 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larmon JE, Magann EF, Dickerson GA, Morrison JC</AU>
<TI>Outpatient cervical ripening with prostaglandin E2 and estradiol</TI>
<SO>Journal of Maternal-Fetal and Neonatal Medicine</SO>
<YR>2002</YR>
<VL>11</VL>
<PG>113-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magann-1995" NAME="Magann 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magann EF, Perry KG, Dockery JR, Bass JD, Chauhan SP, Morrison JC</AU>
<TI>Cervical ripening before medical induction of labor: a comparison of prostaglandin E2, estradiol, and oxytocin</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>172</VL>
<PG>1702-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peedicayil-1990" NAME="Peedicayil 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peedicayil A, Jasper P, Balasubramaniam N, Jairaj P</AU>
<TI>A randomized controlled trial of extra-amniotic ethinyloestradiol for cervical ripening in multiparas</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1990</YR>
<VL>30</VL>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinto-1967" NAME="Pinto 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinto RM, Leon C, Mazzocco N, Scasserra U</AU>
<TI>Action of estradiol-17B at term and at onset of labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1967</YR>
<VL>98</VL>
<PG>540-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quinn-1981" NAME="Quinn 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quinn MA, Murphy AJ, Kuhn RJP, Robinson HP, Brown JB</AU>
<TI>A double blind trial of extra-amniotic oestriol and prostaglandin F2alpha gels in cervical ripening</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1981</YR>
<VL>88</VL>
<PG>644-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tromans-1981" NAME="Tromans 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tromans PM, Beazley JM, Shenouda PI</AU>
<TI>Comparative study of oestradiol and prostaglandin E2 vaginal gel for ripening the unfavourable cervix before induction of labour</TI>
<SO>BMJ</SO>
<YR>1981</YR>
<VL>282</VL>
<PG>679-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-1977" NAME="Gordon 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon AJ, Calder AA</AU>
<TI>Oestradiol applied locally to ripen the unfavourable cervix</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>2</VL>
<PG>1319-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffin-2003" NAME="Griffin 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffin C</AU>
<TI>Outpatient cervical ripening using sequential oestrogen - a randomised controlled pilot study [abstract]</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>2003</YR>
<VL>43</VL>
<PG>183</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klopper-1969" NAME="Klopper 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klopper AI, Dennis KJ, Farr V</AU>
<TI>Effect of intra-amniotic oestriol sulphate on uterine contractions</TI>
<SO>BMJ</SO>
<YR>1969</YR>
<VL>2</VL>
<PG>786-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klopper-1973" NAME="Klopper 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klopper AI, Farr V, Dennis KJ</AU>
<TI>The effect of intra-amniotic oestriol sulphate on uterine contractility at term</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1973</YR>
<VL>80</VL>
<PG>34-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luther-1980" NAME="Luther 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luther ER, Roux J, Popat R, Gardner A, Gray J, Soubiran E, and Korcaz Y</AU>
<TI>The effect of estrogen priming on induction of labor with prostaglandins</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>351-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magnani-1986" NAME="Magnani 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Magnani M, Cabrol D</AU>
<TI>Induction of labour with PGE2 after cervical ripening with oestradiol</TI>
<SO>Control and Management of Parturition</SO>
<YR>1986</YR>
<PG>109-18</PG>
<PB>INSERM</PB>
<CY>Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mamo-1994" NAME="Mamo 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mamo J</AU>
<TI>Intravaginal oestriol pessary for preinduction cervical ripening</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1994</YR>
<VL>46</VL>
<PG>137</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1955" NAME="Martin 1955" YEAR="1955">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin, RH, Menzies, DN</AU>
<TI>Oestrogen therapy in missed abortion and labour</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1955</YR>
<VL>62</VL>
<PG>256-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moran-1994" NAME="Moran 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moran DJ, McGarrigle HHG, Lachelin GCL</AU>
<TI>Maternal plasma progesterone levels fall after rectal administration of estriol</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>1994</YR>
<VL>78</VL>
<NO>1</NO>
<PG>70-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palmero-1997" NAME="Palmero 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palermo MSF, Damiano MS, Lijdens E, Cassale E, Monaco A, Gamarino S et al</AU>
<TI>Dinoprostone vs. oestradiol for induction to delivery. Clinical controlled trial</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1997</YR>
<VL>76</VL>
<PG>97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Pedersen-1981" NAME="Pedersen 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen S, Moller-Petersen J, Aegidius J</AU>
<TI>Comparison of oestradiol and prostaglandin E2 vaginal gel for ripening the unfavourable cervix</TI>
<SO>BMJ</SO>
<YR>1981</YR>
<VL>282</VL>
<PG>1395</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen S, Moller-Petersen, Egidius J</AU>
<TI>The effect on induction of labour of endocervical balloon catheter with and without oestrogen therapy</TI>
<TO>Effekten pa fodselsigangsaettelse af endocerviklat balonkateter med og uden ostraiolbehandling</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1975</YR>
<VL>143</VL>
<PG>3379-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peedicayil-1989" NAME="Peedicayil 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peedicayil A, Jasper P, Balasubramaniam N, Jairaj P</AU>
<TI>A randomized controlled trial of extra-amniotic ethinyloestradiol in ripening the cervix at term</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1989</YR>
<VL>96</VL>
<PG>973-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roztocil-1998" NAME="Roztocil 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roztocil A, Pilka L, Jelinek J, Koudelka M, Miklica J</AU>
<TI>A comparison of three preinduction cervical priming methods: prostaglandin e2 gel, dilapan s rods and estradiol gel</TI>
<SO>Ceska Gynekologie</SO>
<YR>1998</YR>
<VL>63</VL>
<PG>3-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sasaki-1982" NAME="Sasaki 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sasaki K, Nakano R, Kadoya Y, Iwao M, Shima K, Sowa M</AU>
<TI>Cervical ripening with dehydroepiandrosterone sulphate</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1982</YR>
<VL>89</VL>
<PG>195-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stewart-1981" NAME="Stewart 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart P, Kennedy JH, Barlow DH, Calder AA</AU>
<TI>A comparison of oestradiol and prostaglandin E2 for ripening the cervix</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1981</YR>
<VL>88</VL>
<PG>236-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thiery-1978" NAME="Thiery 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thiery M, De Gezelle H, Van Kets H, Voorhoof L, Verheugen C, Smis B et al</AU>
<TI>Extra-amniotic oestrogens for the unfavourable cervix</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>2</VL>
<PG>835-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thiery-1979" NAME="Thiery 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thiery M, De Gezelle H, Van Kets H, Voorhoof L, Verheugen B, Sims J, et al</AU>
<TI>The effect of locally adminstered estrogens on the human cervix</TI>
<SO>Zeitschrift fur Geburtshilfe und Perinatologie</SO>
<YR>1979</YR>
<VL>183</VL>
<PG>448-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-1988" NAME="Williams 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams JK, Lewis ML, Cohen GR, O'Brien WF</AU>
<TI>The sequential use of estradiol and prostaglandin E2 topical gels for cervical ripening in high-risk term pregnancies requiring induction of labour</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>55-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-12 16:37:07 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-12 16:37:07 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alfirevic-2006" MODIFIED="2008-08-12 16:32:41 +0100" MODIFIED_BY="[Empty name]" NAME="Alfirevic 2006" TYPE="COCHRANE_REVIEW">
<AU>Alfirevic Z, Weeks A</AU>
<TI>Oral misoprostol for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:32:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001338.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boulvain-2001" MODIFIED="2008-08-12 14:39:29 +0100" MODIFIED_BY="[Empty name]" NAME="Boulvain 2001" TYPE="COCHRANE_REVIEW">
<AU>Boulvain M, Kelly A, Lohse C, Stan C, Irion O</AU>
<TI>Mechanical methods for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-12 14:39:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001233"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boulvain-2005" MODIFIED="2008-08-12 16:33:08 +0100" MODIFIED_BY="[Empty name]" NAME="Boulvain 2005" TYPE="COCHRANE_REVIEW">
<AU>Boulvain M, Stan C, Irion O</AU>
<TI>Membrane sweeping for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000451.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boulvain-2008" MODIFIED="2008-08-12 16:33:12 +0100" MODIFIED_BY="[Empty name]" NAME="Boulvain 2008" TYPE="COCHRANE_REVIEW">
<AU>Boulvain M, Kelly A, Irion O</AU>
<TI>Intracervical prostaglandins for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006971"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bricker-2000" MODIFIED="2008-08-12 16:33:16 +0100" MODIFIED_BY="[Empty name]" NAME="Bricker 2000" TYPE="COCHRANE_REVIEW">
<AU>Bricker L, Luckas M</AU>
<TI>Amniotomy alone for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002862"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-2008" MODIFIED="2008-08-12 13:39:27 +0100" MODIFIED_BY="[Empty name]" NAME="Cochrane 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [Updated February 2008]</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtis-1987" NAME="Curtis 1987" NOTES="&lt;p&gt;Curtis P, Evans S, Resnick J. Uterine hyperstimulation. The need for standard terminology. J Reprod Med 1987;32:91-95.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Curtis P, Evans S, Resnick J</AU>
<TI>Uterine hyperstimulation. The need for standard terminology</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1987</YR>
<VL>32</VL>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-2001" MODIFIED="2008-08-12 16:33:24 +0100" MODIFIED_BY="[Empty name]" NAME="French 2001" TYPE="COCHRANE_REVIEW">
<AU>French L</AU>
<TI>Oral prostaglandin E2 for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003098"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2000" MODIFIED="2008-08-12 16:23:35 +0100" MODIFIED_BY="[Empty name]" NAME="Hofmeyr 2000" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Alfirevic Z, Kelly T, Kavanagh J, Thomas J, Brocklehurst P, et al</AU>
<TI>Methods for cervical ripening and labour induction in late pregnancy: generic protocol</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-08-12 15:37:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-12 15:37:55 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002074"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2003" MODIFIED="2008-08-12 14:39:29 +0100" MODIFIED_BY="[Empty name]" NAME="Hofmeyr 2003" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Gülmezoglu AM</AU>
<TI>Vaginal misoprostol for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-08-12 14:39:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000941"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Howarth-2001" MODIFIED="2008-08-12 16:33:33 +0100" MODIFIED_BY="[Empty name]" NAME="Howarth 2001" TYPE="COCHRANE_REVIEW">
<AU>Howarth GR, Botha DJ</AU>
<TI>Amniotomy plus intravenous oxytocin for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003250"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2001" MODIFIED="2008-08-12 16:33:37 +0100" MODIFIED_BY="[Empty name]" NAME="Hutton 2001" TYPE="COCHRANE_REVIEW">
<AU>Hutton E, Mozurkewich E</AU>
<TI>Extra-amniotic prostaglandin for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003092"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2001" MODIFIED="2008-08-12 14:39:29 +0100" MODIFIED_BY="[Empty name]" NAME="Kavanagh 2001" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Sexual intercourse for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-12 14:39:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003093"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2005" MODIFIED="2008-08-12 16:33:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kavanagh 2005" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Breast stimulation for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003392.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2006" MODIFIED="2008-08-12 16:33:47 +0100" MODIFIED_BY="[Empty name]" NAME="Kavanagh 2006" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Corticosteroids for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003100.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2006a" MODIFIED="2008-08-12 16:33:50 +0100" MODIFIED_BY="[Empty name]" NAME="Kavanagh 2006a" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Hyaluronidase for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003097.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2001" MODIFIED="2008-08-12 16:33:54 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2001" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Tan B</AU>
<TI>Intravenous oxytocin alone for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2001a" MODIFIED="2008-08-12 16:33:58 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2001a" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Kavanagh J, Thomas J</AU>
<TI>Relaxin for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:33:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003103"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2001b" MODIFIED="2008-08-12 16:34:01 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2001b" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Kavanagh J, Thomas J</AU>
<TI>Castor oil, bath and/or enema for cervical priming and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:34:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003099"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2003" MODIFIED="2008-08-12 16:34:33 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2003" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Kavanagh J, Thomas J</AU>
<TI>Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:34:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003101"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2008" MODIFIED="2008-08-12 16:35:54 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2008" TYPE="COCHRANE_PROTOCOL">
<AU>Kelly T, Doswell T, Alfirevic Z,</AU>
<TI>Outpatient versus inpatient induction of labour for improving birth outcomes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:35:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-12 16:35:54 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007372"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2008a" MODIFIED="2008-08-12 16:36:00 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2008a" TYPE="COCHRANE_PROTOCOL">
<AU>Kelly AJ, Kavanagh J</AU>
<TI>Nitric oxide donors for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:36:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006901"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Luckas-2000" MODIFIED="2008-08-12 16:36:03 +0100" MODIFIED_BY="[Empty name]" NAME="Luckas 2000" TYPE="COCHRANE_REVIEW">
<AU>Luckas M, Bricker L</AU>
<TI>Intravenous prostaglandin for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:36:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002864"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Muzonzini-2004" MODIFIED="2008-08-12 16:36:08 +0100" MODIFIED_BY="[Empty name]" NAME="Muzonzini 2004" TYPE="COCHRANE_REVIEW">
<AU>Muzonzini G, Hofmeyr GJ</AU>
<TI>Buccal or sublingual misoprostol for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:36:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004221.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neilson-2000" MODIFIED="2008-08-12 16:36:12 +0100" MODIFIED_BY="[Empty name]" NAME="Neilson 2000" TYPE="COCHRANE_REVIEW">
<AU>Neilson JP</AU>
<TI>Mifepristone for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:36:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002865"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2008-08-12 16:36:54 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2003" MODIFIED="2008-08-12 16:36:59 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2003" TYPE="COCHRANE_REVIEW">
<AU>Smith CA</AU>
<TI>Homoeopathy for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:36:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003399"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smith-2004" MODIFIED="2008-08-12 15:16:02 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2004" TYPE="COCHRANE_REVIEW">
<AU>Smith CA, Crowther CA</AU>
<TI>Acupuncture for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-08-12 15:16:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-12 15:16:02 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002962.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2001" MODIFIED="2008-08-12 16:37:07 +0100" MODIFIED_BY="[Empty name]" NAME="Thomas 2001" TYPE="COCHRANE_REVIEW">
<AU>Thomas J, Kelly AJ, Kavanagh J</AU>
<TI>Oestrogens alone or with amniotomy for cervical ripening or induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-12 16:37:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003393"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-08-12 16:05:31 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-12 16:05:31 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-08-12 13:03:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klopper-1962">
<CHAR_METHODS>
<P>No mention of method of randomisation or concealment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-04 14:14:54 +0100" MODIFIED_BY="[Empty name]">
<P>44 nulliparous women, &gt; 37 weeks pregnant. Not stated if IP or OP setting</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-12 13:03:59 +0100" MODIFIED_BY="[Empty name]">
<P>10 mg oral oestradiol (20 mg initially, followed by 10 mg 6 hourly)<BR/>vs<BR/>placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Caesarean section.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-12 12:59:16 +0100" MODIFIED_BY="[Empty name]">
<P>Not stated if inpatient or outpatient setting, University of Aberdeen, UK. Two trials reported, only smaller first trial is definite RCT. Funding not stated but Intervention and placebo donated by pharmaceutical company Organnon.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-12 16:05:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Larmon-2002">
<CHAR_METHODS MODIFIED="2008-08-12 13:00:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation by random number tables, concealment by opaque numbered envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-12 13:00:18 +0100" MODIFIED_BY="[Empty name]">
<P>87 pregnant women&gt; 37 weeks, unfavourable cervix (Bishops score &lt;6), outpatient setting.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-12 16:05:31 +0100" MODIFIED_BY="[Empty name]">
<P>0.5 mg PGE2 intracervical gel versus 4 mg vaginal oestrogen gel versus inert gel. All given weekly until spontaneous labour or membrane rupture. No maximum specified.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-12 13:01:31 +0100" MODIFIED_BY="[Empty name]">
<P>Caesarean section, oxytocin augmentation, instrumental vaginal delivery, meconium stained liquor, neonatal intensive care unit admission, serious maternal complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-04 14:49:13 +0100" MODIFIED_BY="[Empty name]">
<P>Outpatient setting. University of Mississippi Medical centre, USA. Funded in part by the Vicksburg Medical Foundation, Mississippi.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-12 13:03:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Magann-1995">
<CHAR_METHODS>
<P>Computer generated sequence, allocation by sealed opaque envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-12 13:01:56 +0100" MODIFIED_BY="[Empty name]">
<P>99 pregnant women (33 in each treatment group), with intact membranes, Bishops score &lt; 4. Setting not stated but probably an inpatient setting.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-12 13:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>4 mg vaginal oestradiol cream (6 hourly, max 3 doses)<BR/>vs<BR/>0.5 mg intracervical PGE2 gel (6 hourly, max 3 doses)<BR/>vs<BR/>IV oxytocin (starting at 1mU/min increased every 30 minutes).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Caesarean section, instrumental vaginal delivery.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-04 14:51:02 +0100" MODIFIED_BY="[Empty name]">
<P>University of Mississippi Medical centre, USA. Setting not stated but probably an inpatient setting. Source of funding not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-12 13:03:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peedicayil-1990">
<CHAR_METHODS>
<P>Randomisation method unclear, concealment by coded drug boxes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-12 13:03:27 +0100" MODIFIED_BY="[Empty name]">
<P>50 Multiparae, unfavourable cervix (Bishops score &lt; 3), singleton, cephalic, &gt; 37 weeks. Not stated if IP or OP.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-12 13:03:42 +0100" MODIFIED_BY="[Empty name]">
<P>150 mg extra amniotic oestradiol<BR/>vs<BR/>extra amniotic placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Caesarean section, perinatal mortality, instrumental vaginal delivery.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-04 14:52:56 +0100" MODIFIED_BY="[Empty name]">
<P>Christian medical college and hospital, Vellore, India.<BR/>Setting not stated but probably an inpatient. Source of funding not stated. </P>
<P>Unclear from report to what volume the catheter was inflated to.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-12 13:04:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pinto-1967">
<CHAR_METHODS>
<P>Alternation used for allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-04 14:15:52 +0100" MODIFIED_BY="[Empty name]">
<P>100 pregnant women &gt; 36 weeks. Inpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-12 13:04:57 +0100" MODIFIED_BY="[Empty name]">
<P>200 mg single dose of IV oestradiol<BR/>vs<BR/>IV placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Caesarean section.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-04 14:54:51 +0100" MODIFIED_BY="[Empty name]">
<P>University of Buenos Aires, Argentina.<BR/>Inpatient setting. Source of funding not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-12 13:05:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quinn-1981">
<CHAR_METHODS>
<P>Randomisation method not mentioned. Drugs prepared in coded bottles.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-04 14:16:20 +0100" MODIFIED_BY="[Empty name]">
<P>25 Nulliparous women with modified Bishops score, 3. Inpatients for procedure.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-12 13:05:17 +0100" MODIFIED_BY="[Empty name]">
<P>15 mg extra amniotic oestradiol<BR/>vs<BR/>10 mg extra amniotic PGF2a<BR/>vs<BR/>extra amniotic placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Uterine hyperstimulation, caesarean section, instrumental vaginal delivery, perinatal death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-04 14:57:57 +0100" MODIFIED_BY="[Empty name]">
<P>Dalhousie university, Halifax, Canada.<BR/>Inpatient setting. Source of funding not stated. Prostaglandin supplied by Upjohn pty Ltd and Hoechst Australia Ltd supplied the Tylose gel.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-12 13:05:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tromans-1981">
<CHAR_METHODS>
<P>Allocation by date of admission.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-04 14:16:42 +0100" MODIFIED_BY="[Empty name]">
<P>60 women with singleton cephalic pregnancy, &gt; 37 weeks, presentation unfavourable cervix &lt; 4 on modified Bishops score. Inpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-12 13:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>150 mg intravaginal oestradiol<BR/>vs<BR/>4 mg vaginal PGE2<BR/>Both in a tylose gel.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Uterine hyperstimulation, caesarean section, epidural analgesia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-04 14:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Royal Liverpool Hospital, UK.<BR/>Inpatient setting. Source of funding not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>SRM=artificial rupture of the membranes<BR/>IV = intravenous</P>
<P>IP = inpatient</P>
<P>min = minimum<BR/>max = maximum</P>
<P>OP = outpatient<BR/>RCT = randomised controlled trial<BR/>vs = versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-08-12 13:12:09 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-08-12 13:07:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gordon-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-12 13:07:49 +0100" MODIFIED_BY="[Empty name]">
<P>Complex intervention. Both groups had extra-amniotic Foley catheter (balloon inflated to 20 mls) with either extra-amniotic oestrogen or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-12 13:08:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Griffin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-12 13:08:14 +0100" MODIFIED_BY="[Empty name]">
<P>No prespecified outcomes reported in usable format. 35 women randomised to either 12 mg oestradiol twice a day for two days or placebo as outpatients prior to Induction of labour. The main outcome measured was change (improvement) in Bishops score. Published as abstract.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klopper-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an induction trial, but uterine activity study. ARM given and then intra-amniotic oestriol sulphate at onset of labour to test if myometrial activity is modified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klopper-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uterine activity study. No pre-specified outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-12 13:08:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luther-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-12 13:08:45 +0100" MODIFIED_BY="[Empty name]">
<P>Complex intervention. groups randomised to either 10 mg intramuscular estradiol valerate or placebo followed by oral prostaglandin E2.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-12 13:09:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Magnani-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-12 13:09:04 +0100" MODIFIED_BY="[Empty name]">
<P>Report of two trials. First trial compares vaginal oestrogen with placebo, but no pre-specified outcomes are reported. The second trial involves a complex intervention of oestrogen or placebo followed by extra-amniotic prostaglandin 12 hours later.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mamo-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No pre-specified outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin-1955">
<CHAR_REASON_FOR_EXCLUSION>
<P>IOL for failed abortion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-02 12:49:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moran-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-02 12:49:52 +0100" MODIFIED_BY="[Empty name]">
<P>No prespecified outcomes reported. 28 women included, 17 received rectal estriol and 11 received placebo. The outcome was measurement of plasma progesterone levels.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Palmero-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No pre-specified outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pedersen-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>No pre-specified outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-12 13:11:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peedicayil-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-12 13:11:19 +0100" MODIFIED_BY="[Empty name]">
<P>Complex intervention, Both groups had extra-amniotic Foley catheter (balloon inflated to 10mls) with either extra-amniotic oestrogen or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roztocil-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Complex intervention. Second phase allocated on Bishops score.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sasaki-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Induction with Dehydroepiandrosterone sulphate versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-12 13:11:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stewart-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-12 13:11:51 +0100" MODIFIED_BY="[Empty name]">
<P>Complex intervention. Both groups had extra-amniotic Foley catheter (balloon inflated to 20 mls) with either extra-amniotic oestrogen or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thiery-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No pre-specified outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-12 13:12:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thiery-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-12 13:12:09 +0100" MODIFIED_BY="[Empty name]">
<P>Complex intervention. Both groups had extra-amniotic Foley catheter (balloon inflated to 20 mls) with either extra-amniotic oestrogen or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Williams-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indications for induction included fetal death.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ARM = artificial rupture of the membranes<BR/>IOL = induction of labour</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klopper-1962">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Larmon-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Magann-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Peedicayil-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Pinto-1967">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Quinn-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Tromans-1981">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Methodological quality of trials</TITLE>
<TABLE COLS="3" ROWS="3">
<TR>
<TH>
<P>Methodological item</P>
</TH>
<TH>
<P>Adequate</P>
</TH>
<TH>
<P>Inadequate</P>
</TH>
</TR>
<TR>
<TD>
<P>Generation of random sequence</P>
</TD>
<TD>
<P>Computer generated sequence, random number tables, lot drawing, coin tossing, shuffling cards, throwing dice.</P>
</TD>
<TD>
<P>Case number, date of birth, date of admission, alternation.</P>
</TD>
</TR>
<TR>
<TD>
<P>Concealment of allocation</P>
</TD>
<TD>
<P>Central randomisation, coded drug boxes, sequentially sealed opaque envelopes.</P>
</TD>
<TD>
<P>Open allocation sequence, any procedure based on inadequate generation.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Oestrogen versus placebo: all women</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="64.87500144203905" CI_START="0.1821411327529152" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4374999999999996" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.8120773805099955" LOG_CI_START="-0.7395919668333574" LOG_EFFECT_SIZE="0.536242706838319" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.4100604366971322" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.8237872931848573">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.87500144203905" CI_START="0.1821411327529152" EFFECT_SIZE="3.4375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8120773805099955" LOG_CI_START="-0.7395919668333574" LOG_EFFECT_SIZE="0.5362427068383191" ORDER="1" O_E="0.0" SE="1.4988632055964644" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.246590909090909" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4558763944540547" CI_END="1.6782775186572105" CI_START="0.6010953426793533" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0043927519592675" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.22486377702662502" LOG_CI_START="-0.22105663695650907" LOG_EFFECT_SIZE="0.0019035700350579952" METHOD="MH" NO="3" P_CHI2="0.4846193758794223" P_Q="0.0" P_Z="0.9866491355761562" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="150" WEIGHT="100.00000000000001" Z="0.01673360803304436">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.612650889751295" CI_START="0.007811285979830553" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4170813818728008" LOG_CI_START="-2.107277461901315" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="2" O_E="0.0" SE="1.4828208806107213" STUDY_ID="STD-Klopper-1962" TOTAL_1="22" TOTAL_2="22" VAR="2.1987577639751548" WEIGHT="15.199920131782562"/>
<DICH_DATA CI_END="2.5648524877873657" CI_START="0.6924147541653146" EFFECT_SIZE="1.3326446280991735" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.40906239261268024" LOG_CI_START="-0.15963368663096966" LOG_EFFECT_SIZE="0.12471435299085529" ORDER="3" O_E="0.0" SE="0.3340548920387134" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.11159267089499648" WEIGHT="48.32027155193931"/>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="4.342834323366446"/>
<DICH_DATA CI_END="3.6786074906021238" CI_START="0.39145247316513704" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5656834508483586" LOG_CI_START="-0.4073209587531089" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="5" O_E="0.0" SE="0.5715476066494082" STUDY_ID="STD-Pinto-1967" TOTAL_1="50" TOTAL_2="50" VAR="0.32666666666666666" WEIGHT="21.714171616832232"/>
<DICH_DATA CI_END="3.204509958070007" CI_START="0.03467335491696534" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5057616254997813" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="6" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="1.3333333333333333" WEIGHT="10.42280237607947"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.116785694102392" CI_START="0.06615162907218672" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="35" WEIGHT="100.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="7" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.312776554025594E-31" CI_END="1.4273355488007557" CI_START="0.6096754446310303" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9328512396694214" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="100.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.15452608233814732" LOG_CI_START="-0.21490129632792307" LOG_EFFECT_SIZE="-0.03018760699488791" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.7487293195866735" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="0.32031530907681377">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4273355488007557" CI_START="0.6096754446310303" EFFECT_SIZE="0.9328512396694215" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.15452608233814732" LOG_CI_START="-0.21490129632792307" LOG_EFFECT_SIZE="-0.03018760699488786" ORDER="9" O_E="0.0" SE="0.21700347092346697" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.04709050639283198" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="10" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6723580273543748" CI_END="1.222983421616555" CI_START="0.4594921647422149" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.749634110644941" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.08742056991506825" LOG_CI_START="-0.337721889801771" LOG_EFFECT_SIZE="-0.1251506599433514" METHOD="MH" NO="11" P_CHI2="0.7144952617544339" P_Q="0.0" P_Z="0.2485318454705353" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="78" WEIGHT="100.0" Z="1.1539227876404592">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5988553224072208" CI_START="0.43886284275020737" EFFECT_SIZE="0.8376623376623377" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.20380916698393176" LOG_CI_START="-0.35767118805835996" LOG_EFFECT_SIZE="-0.0769310105372141" ORDER="11" O_E="0.0" SE="0.3298163399244247" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.10877881808114366" WEIGHT="60.10342472436336"/>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="12" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="4.24431651868475"/>
<DICH_DATA CI_END="1.1986320720361552" CI_START="0.27241938528326687" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="13" O_E="0.0" SE="0.37796447300922725" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.14285714285714288" WEIGHT="35.6522587569519"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.714866182840065E-32" CI_END="1.8303409599647864" CI_START="0.13044864377201182" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4886363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="100.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.2625319986038402" LOG_CI_START="-0.8845604317450044" LOG_EFFECT_SIZE="-0.31101421657058215" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.28786338637780495" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.0628204790313227">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8303409599647866" CI_START="0.13044864377201182" EFFECT_SIZE="0.48863636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.26253199860384024" LOG_CI_START="-0.8845604317450044" LOG_EFFECT_SIZE="-0.3110142165705821" ORDER="14" O_E="0.0" SE="0.6738077717860184" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.45401691331923894" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.131350376360228" CI_START="0.06311809321150688" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9772727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="1.1798776877609272" LOG_CI_START="-1.1998461295741287" LOG_EFFECT_SIZE="-0.009984220906600895" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.9868784181158463" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="100.0" Z="0.01644620543617848">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.131350376360228" CI_START="0.06311809321150688" EFFECT_SIZE="0.9772727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1798776877609272" LOG_CI_START="-1.1998461295741287" LOG_EFFECT_SIZE="-0.009984220906600895" ORDER="15" O_E="0.0" SE="1.3978615501254903" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="1.9540169133192389" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8107039169243295" CI_START="0.014225492643544472" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.49481017826454565" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="35" WEIGHT="100.0" Z="0.68267825417953">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8107039169243295" CI_START="0.014225492643544472" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="16" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.10293959909722" CI_START="0.8507977076303366" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9318181818181817" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="1.0044477565468615" LOG_CI_START="-0.07017368892073848" LOG_EFFECT_SIZE="0.4671370338130615" METHOD="MH" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="0.08838307241198569" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.7039893740815446">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.10293959909722" CI_START="0.8507977076303368" EFFECT_SIZE="2.9318181818181817" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0044477565468615" LOG_CI_START="-0.07017368892073837" LOG_EFFECT_SIZE="0.4671370338130615" ORDER="18" O_E="0.0" SE="0.6312379565296143" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.39846135776368335" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Oestrogen versus placebo: all women, unfavourable</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="64.87500144203905" CI_START="0.1821411327529152" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4374999999999996" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="1.8120773805099955" LOG_CI_START="-0.7395919668333574" LOG_EFFECT_SIZE="0.536242706838319" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.4100604366971322" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.8237872931848573">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.87500144203905" CI_START="0.1821411327529152" EFFECT_SIZE="3.4375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8120773805099955" LOG_CI_START="-0.7395919668333574" LOG_EFFECT_SIZE="0.5362427068383191" ORDER="19" O_E="0.0" SE="1.4988632055964644" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.246590909090909" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3582628757644288" CI_END="2.092706244220936" CI_START="0.6260830544018486" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1446431397373003" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.320708270160238" LOG_CI_START="-0.20336805069398187" LOG_EFFECT_SIZE="0.05867010973312805" METHOD="MH" NO="3" P_CHI2="0.5070572578934132" P_Q="0.0" P_Z="0.6607816910081799" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="78" WEIGHT="100.0" Z="0.4388341830003441">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5648524877873657" CI_START="0.6924147541653146" EFFECT_SIZE="1.3326446280991735" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.40906239261268024" LOG_CI_START="-0.15963368663096966" LOG_EFFECT_SIZE="0.12471435299085529" ORDER="20" O_E="0.0" SE="0.3340548920387134" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.11159267089499648" WEIGHT="76.59439784776072"/>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="21" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="6.884000633011553"/>
<DICH_DATA CI_END="3.204509958070007" CI_START="0.03467335491696534" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5057616254997813" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="22" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="1.3333333333333333" WEIGHT="16.521601519227726"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.116785694102392" CI_START="0.06615162907218672" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="35" WEIGHT="100.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="23" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.312776554025594E-31" CI_END="1.4273355488007557" CI_START="0.6096754446310303" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9328512396694214" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="100.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.15452608233814732" LOG_CI_START="-0.21490129632792307" LOG_EFFECT_SIZE="-0.03018760699488791" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.7487293195866735" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="0.32031530907681377">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4273355488007557" CI_START="0.6096754446310303" EFFECT_SIZE="0.9328512396694215" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.15452608233814732" LOG_CI_START="-0.21490129632792307" LOG_EFFECT_SIZE="-0.03018760699488786" ORDER="25" O_E="0.0" SE="0.21700347092346697" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.04709050639283198" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="26" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6723580273543748" CI_END="1.222983421616555" CI_START="0.4594921647422149" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.749634110644941" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.08742056991506825" LOG_CI_START="-0.337721889801771" LOG_EFFECT_SIZE="-0.1251506599433514" METHOD="MH" NO="11" P_CHI2="0.7144952617544339" P_Q="0.0" P_Z="0.2485318454705353" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="78" WEIGHT="100.0" Z="1.1539227876404592">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5988553224072208" CI_START="0.43886284275020737" EFFECT_SIZE="0.8376623376623377" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.20380916698393176" LOG_CI_START="-0.35767118805835996" LOG_EFFECT_SIZE="-0.0769310105372141" ORDER="27" O_E="0.0" SE="0.3298163399244247" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.10877881808114366" WEIGHT="60.10342472436336"/>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="28" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="4.24431651868475"/>
<DICH_DATA CI_END="1.1986320720361552" CI_START="0.27241938528326687" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="29" O_E="0.0" SE="0.37796447300922725" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.14285714285714288" WEIGHT="35.6522587569519"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.714866182840065E-32" CI_END="1.8303409599647864" CI_START="0.13044864377201182" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4886363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="100.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.2625319986038402" LOG_CI_START="-0.8845604317450044" LOG_EFFECT_SIZE="-0.31101421657058215" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.28786338637780495" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.0628204790313227">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8303409599647866" CI_START="0.13044864377201182" EFFECT_SIZE="0.48863636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.26253199860384024" LOG_CI_START="-0.8845604317450044" LOG_EFFECT_SIZE="-0.3110142165705821" ORDER="30" O_E="0.0" SE="0.6738077717860184" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.45401691331923894" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.131350376360228" CI_START="0.06311809321150688" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9772727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="1.1798776877609272" LOG_CI_START="-1.1998461295741287" LOG_EFFECT_SIZE="-0.009984220906600895" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.9868784181158463" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="100.0" Z="0.01644620543617848">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.131350376360228" CI_START="0.06311809321150688" EFFECT_SIZE="0.9772727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1798776877609272" LOG_CI_START="-1.1998461295741287" LOG_EFFECT_SIZE="-0.009984220906600895" ORDER="31" O_E="0.0" SE="1.3978615501254903" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="1.9540169133192389" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8107039169243295" CI_START="0.014225492643544472" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.49481017826454565" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="35" WEIGHT="100.0" Z="0.68267825417953">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8107039169243295" CI_START="0.014225492643544472" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="32" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.10293959909722" CI_START="0.8507977076303366" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9318181818181817" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="1.0044477565468615" LOG_CI_START="-0.07017368892073848" LOG_EFFECT_SIZE="0.4671370338130615" METHOD="MH" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="0.08838307241198569" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.7039893740815446">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.10293959909722" CI_START="0.8507977076303368" EFFECT_SIZE="2.9318181818181817" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0044477565468615" LOG_CI_START="-0.07017368892073837" LOG_EFFECT_SIZE="0.4671370338130615" ORDER="34" O_E="0.0" SE="0.6312379565296143" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.39846135776368335" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Oestrogen versus placebo: all women, intact membranes, unfavourable</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5648524877873657" CI_START="0.6924147541653146" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3326446280991735" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.40906239261268024" LOG_CI_START="-0.15963368663096966" LOG_EFFECT_SIZE="0.12471435299085529" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.3899900647567722" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="0.8596353980227338">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5648524877873657" CI_START="0.6924147541653146" EFFECT_SIZE="1.3326446280991735" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.40906239261268024" LOG_CI_START="-0.15963368663096966" LOG_EFFECT_SIZE="0.12471435299085529" ORDER="35" O_E="0.0" SE="0.3340548920387134" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.11159267089499648" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.312776554025594E-31" CI_END="1.4273355488007557" CI_START="0.6096754446310303" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9328512396694214" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="100.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.15452608233814732" LOG_CI_START="-0.21490129632792307" LOG_EFFECT_SIZE="-0.03018760699488791" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.7487293195866735" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="0.32031530907681377">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4273355488007557" CI_START="0.6096754446310303" EFFECT_SIZE="0.9328512396694215" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.15452608233814732" LOG_CI_START="-0.21490129632792307" LOG_EFFECT_SIZE="-0.03018760699488786" ORDER="36" O_E="0.0" SE="0.21700347092346697" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.04709050639283198" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5988553224072206" CI_START="0.4388628427502074" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8376623376623377" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.2038091669839317" LOG_CI_START="-0.35767118805835985" LOG_EFFECT_SIZE="-0.0769310105372141" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.5912072512284743" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="100.0" Z="0.5370873926153799">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5988553224072208" CI_START="0.43886284275020737" EFFECT_SIZE="0.8376623376623377" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.20380916698393176" LOG_CI_START="-0.35767118805835996" LOG_EFFECT_SIZE="-0.0769310105372141" ORDER="37" O_E="0.0" SE="0.3298163399244247" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.10877881808114366" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.714866182840065E-32" CI_END="1.8303409599647864" CI_START="0.13044864377201182" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4886363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="100.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.2625319986038402" LOG_CI_START="-0.8845604317450044" LOG_EFFECT_SIZE="-0.31101421657058215" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.28786338637780495" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.0628204790313227">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8303409599647866" CI_START="0.13044864377201182" EFFECT_SIZE="0.48863636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.26253199860384024" LOG_CI_START="-0.8845604317450044" LOG_EFFECT_SIZE="-0.3110142165705821" ORDER="38" O_E="0.0" SE="0.6738077717860184" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.45401691331923894" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.131350376360228" CI_START="0.06311809321150688" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9772727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="1.1798776877609272" LOG_CI_START="-1.1998461295741287" LOG_EFFECT_SIZE="-0.009984220906600895" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.9868784181158463" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="100.0" Z="0.01644620543617848">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.131350376360228" CI_START="0.06311809321150688" EFFECT_SIZE="0.9772727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1798776877609272" LOG_CI_START="-1.1998461295741287" LOG_EFFECT_SIZE="-0.009984220906600895" ORDER="39" O_E="0.0" SE="1.3978615501254903" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="1.9540169133192389" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.10293959909722" CI_START="0.8507977076303366" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9318181818181817" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="1.0044477565468615" LOG_CI_START="-0.07017368892073848" LOG_EFFECT_SIZE="0.4671370338130615" METHOD="MH" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="0.08838307241198569" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.7039893740815446">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.10293959909722" CI_START="0.8507977076303368" EFFECT_SIZE="2.9318181818181817" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0044477565468615" LOG_CI_START="-0.07017368892073837" LOG_EFFECT_SIZE="0.4671370338130615" ORDER="40" O_E="0.0" SE="0.6312379565296143" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="43" VAR="0.39846135776368335" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Oestrogen versus placebo: all women, intact membranes, variable or undefined cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6126508897512957" CI_START="0.007811285979830553" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.4170813818728009" LOG_CI_START="-2.107277461901315" LOG_EFFECT_SIZE="-0.8450980400142569" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.1894179524282599" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="1.3123029048888641">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.612650889751295" CI_START="0.007811285979830553" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4170813818728008" LOG_CI_START="-2.107277461901315" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="41" O_E="0.0" SE="1.4828208806107213" STUDY_ID="STD-Klopper-1962" TOTAL_1="22" TOTAL_2="22" VAR="2.1987577639751548" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Oestrogen versus placebo: all primiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="64.87500144203905" CI_START="0.1821411327529152" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4374999999999996" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="1.8120773805099955" LOG_CI_START="-0.7395919668333574" LOG_EFFECT_SIZE="0.536242706838319" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.4100604366971322" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.8237872931848573">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.87500144203905" CI_START="0.1821411327529152" EFFECT_SIZE="3.4375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8120773805099955" LOG_CI_START="-0.7395919668333574" LOG_EFFECT_SIZE="0.5362427068383191" ORDER="42" O_E="0.0" SE="1.4988632055964644" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.246590909090909" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2139292861159807" CI_END="1.3216306975492578" CI_START="0.03673436727968569" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22033898305084743" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.12111011746224877" LOG_CI_START="-1.4349274361328637" LOG_EFFECT_SIZE="-0.6569086593353075" METHOD="MH" NO="3" P_CHI2="0.6437049625016718" P_Q="0.0" P_Z="0.09795155400766879" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="32" WEIGHT="99.99999999999999" Z="1.6548666328199837">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.612650889751295" CI_START="0.007811285979830553" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4170813818728008" LOG_CI_START="-2.107277461901315" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="43" O_E="0.0" SE="1.4828208806107213" STUDY_ID="STD-Klopper-1962" TOTAL_1="22" TOTAL_2="22" VAR="2.1987577639751548" WEIGHT="59.32203389830508"/>
<DICH_DATA CI_END="3.204509958070007" CI_START="0.03467335491696534" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5057616254997813" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="44" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="1.3333333333333333" WEIGHT="40.677966101694906"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="45" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="46" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1986320720361552" CI_START="0.2724193852832669" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.13871207429144086" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="1.480604204622589">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1986320720361552" CI_START="0.27241938528326687" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="47" O_E="0.0" SE="0.37796447300922725" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.14285714285714288" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="48" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Oestrogen versus placebo: all primiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="64.87500144203905" CI_START="0.1821411327529152" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4374999999999996" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="1.8120773805099955" LOG_CI_START="-0.7395919668333574" LOG_EFFECT_SIZE="0.536242706838319" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.4100604366971322" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.8237872931848573">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.87500144203905" CI_START="0.1821411327529152" EFFECT_SIZE="3.4375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8120773805099955" LOG_CI_START="-0.7395919668333574" LOG_EFFECT_SIZE="0.5362427068383191" ORDER="49" O_E="0.0" SE="1.4988632055964644" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.246590909090909" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2045099580700085" CI_START="0.03467335491696534" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.5057616254997814" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.34138810212716" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.951426150896346">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.204509958070007" CI_START="0.03467335491696534" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5057616254997813" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="50" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="1.3333333333333333" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="51" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="52" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1986320720361552" CI_START="0.2724193852832669" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-006.11" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.13871207429144086" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="1.480604204622589">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1986320720361552" CI_START="0.27241938528326687" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="53" O_E="0.0" SE="0.37796447300922725" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.14285714285714288" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="54" O_E="0.0" SE="0.0" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Oestrogen versus placebo: all multiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.116785694102392" CI_START="0.06615162907218672" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="55" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.116785694102392" CI_START="0.06615162907218672" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="56" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.116785694102392" CI_START="0.06615162907218672" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.11" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="57" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8107039169243295" CI_START="0.014225492643544472" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.16" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.49481017826454565" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.68267825417953">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8107039169243295" CI_START="0.014225492643544472" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="58" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Oestrogen versus placebo: all multiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.116785694102392" CI_START="0.06615162907218672" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="59" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.116785694102392" CI_START="0.06615162907218672" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="60" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.116785694102392" CI_START="0.06615162907218672" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.11" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.116785694102392" CI_START="0.06615162907218672" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1794594562633327" LOG_CI_START="-1.1794594562633327" LOG_EFFECT_SIZE="0.0" ORDER="61" O_E="0.0" SE="1.3856406460551018" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="1.92" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8107039169243295" CI_START="0.014225492643544472" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.16" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.49481017826454565" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.68267825417953">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8107039169243295" CI_START="0.014225492643544472" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="62" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Peedicayil-1990" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Oestrogen versus placebo: all primiparae, intact membranes, variable or undefined cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6126508897512957" CI_START="0.007811285979830553" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.4170813818728009" LOG_CI_START="-2.107277461901315" LOG_EFFECT_SIZE="-0.8450980400142569" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.1894179524282599" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="1.3123029048888641">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.612650889751295" CI_START="0.007811285979830553" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4170813818728008" LOG_CI_START="-2.107277461901315" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="63" O_E="0.0" SE="1.4828208806107213" STUDY_ID="STD-Klopper-1962" TOTAL_1="22" TOTAL_2="22" VAR="2.1987577639751548" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Oestrogen versus vaginal prostaglandins: all women</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="99.95416281504153" CI_START="0.25011464551267176" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.2922772002054833" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.053139231306288">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="64" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Tromans-1981" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1076971966517677" CI_START="0.36325189463469976" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.3238082178928757" LOG_CI_START="-0.43979211184824923" LOG_EFFECT_SIZE="-0.057991946977686754" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.7659317072260966" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.29770057199466143">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1076971966517677" CI_START="0.36325189463469976" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3238082178928757" LOG_CI_START="-0.43979211184824923" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="65" O_E="0.0" SE="0.4485426135725302" STUDY_ID="STD-Tromans-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.2011904761904762" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.487677392109312" CI_START="2.0176059206321786" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.6" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-010.08" LOG_CI_END="1.0206793197020878" LOG_CI_START="0.3048363436610602" LOG_EFFECT_SIZE="0.6627578316815741" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="2.8426148784666894E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="3.62923580741622">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.487677392109312" CI_START="2.0176059206321786" EFFECT_SIZE="4.6" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="5" LOG_CI_END="1.0206793197020878" LOG_CI_START="0.3048363436610602" LOG_EFFECT_SIZE="0.6627578316815741" ORDER="66" O_E="0.0" SE="0.42048970760637955" STUDY_ID="STD-Tromans-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.17681159420289858" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2879222518327607" CI_START="0.7764443844160338" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-010.10" LOG_CI_END="0.10988964670457296" LOG_CI_START="-0.10988964670457302" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>Epidural analgesia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2879222518327607" CI_START="0.7764443844160338" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.10988964670457296" LOG_CI_START="-0.10988964670457302" LOG_EFFECT_SIZE="0.0" ORDER="67" O_E="0.0" SE="0.12909944487358055" STUDY_ID="STD-Tromans-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.016666666666666663" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Oestrogen versus vaginal prostaglandins: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="99.95416281504153" CI_START="0.25011464551267176" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.2922772002054833" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.053139231306288">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="68" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Tromans-1981" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1076971966517677" CI_START="0.36325189463469976" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="0.3238082178928757" LOG_CI_START="-0.43979211184824923" LOG_EFFECT_SIZE="-0.057991946977686754" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.7659317072260966" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.29770057199466143">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1076971966517677" CI_START="0.36325189463469976" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3238082178928757" LOG_CI_START="-0.43979211184824923" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="69" O_E="0.0" SE="0.4485426135725302" STUDY_ID="STD-Tromans-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.2011904761904762" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.487677392109312" CI_START="2.0176059206321786" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.6" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-011.08" LOG_CI_END="1.0206793197020878" LOG_CI_START="0.3048363436610602" LOG_EFFECT_SIZE="0.6627578316815741" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="2.8426148784666894E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="3.62923580741622">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.487677392109312" CI_START="2.0176059206321786" EFFECT_SIZE="4.6" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="5" LOG_CI_END="1.0206793197020878" LOG_CI_START="0.3048363436610602" LOG_EFFECT_SIZE="0.6627578316815741" ORDER="70" O_E="0.0" SE="0.42048970760637955" STUDY_ID="STD-Tromans-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.17681159420289858" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2879222518327607" CI_START="0.7764443844160338" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-011.10" LOG_CI_END="0.10988964670457296" LOG_CI_START="-0.10988964670457302" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>Epidural analgesia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2879222518327607" CI_START="0.7764443844160338" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.10988964670457296" LOG_CI_START="-0.10988964670457302" LOG_EFFECT_SIZE="0.0" ORDER="71" O_E="0.0" SE="0.12909944487358055" STUDY_ID="STD-Tromans-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.016666666666666663" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" NO="15">
<NAME>Oestrogen versus intracervical prostaglandins: all women</NAME>
<DICH_OUTCOME CHI2="3.495971735774927" CI_END="1.954474162991056" CI_START="0.9017585436266015" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.327578161455903" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="25" I2="71.3956497483428" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="0.2910299336863629" LOG_CI_START="-0.0449097343078402" LOG_EFFECT_SIZE="0.12306009968926132" METHOD="MH" NO="3" P_CHI2="0.06151842031567034" P_Q="0.0" P_Z="0.15102151613001108" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="74" WEIGHT="100.0" Z="1.435932617097323">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.427350865171095" CI_START="0.999895190049098" EFFECT_SIZE="2.3295454545454546" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.7345878985800531" LOG_CI_START="-4.55207688817414E-5" LOG_EFFECT_SIZE="0.3672711889055857" ORDER="72" O_E="0.0" SE="0.43152730701963876" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.18621581670362158" WEIGHT="24.638357442837144"/>
<DICH_DATA CI_END="1.513135544565797" CI_START="0.6608793267670913" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.17987783325803164" LOG_CI_START="-0.17987783325803167" LOG_EFFECT_SIZE="0.0" ORDER="73" O_E="0.0" SE="0.21132225933080553" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.04465709728867623" WEIGHT="75.36164255716285"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3643561051479853" CI_START="0.8262890368637346" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3977272727272727" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-015.07" LOG_CI_END="0.3737128879679299" LOG_CI_START="-0.08286800938947138" LOG_EFFECT_SIZE="0.1454224392892293" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.21184463655348362" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="1.24850927929971">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3643561051479853" CI_START="0.8262890368637346" EFFECT_SIZE="1.3977272727272727" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.3737128879679299" LOG_CI_START="-0.08286800938947138" LOG_EFFECT_SIZE="0.1454224392892293" ORDER="74" O_E="0.0" SE="0.26819787921963006" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.07193010241790729" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17168801045978077" CI_END="1.2343578974334533" CI_START="0.3887053547832015" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6926770708283313" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-015.11" LOG_CI_END="0.09144110000894747" LOG_CI_START="-0.4103794765110598" LOG_EFFECT_SIZE="-0.15946918825105616" METHOD="MH" NO="11" P_CHI2="0.6786162394572846" P_Q="0.0" P_Z="0.21288201421528463" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="74" WEIGHT="100.0" Z="1.2456797518483052">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2035822249060135" CI_START="0.35946055835062596" EFFECT_SIZE="0.6577540106951871" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.08047576524099329" LOG_CI_START="-0.4443487554351955" LOG_EFFECT_SIZE="-0.18193649509710105" ORDER="75" O_E="0.0" SE="0.3082845213684694" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.09503934611538628" WEIGHT="89.79591836734694"/>
<DICH_DATA CI_END="6.683507312873237" CI_START="0.1496220402233839" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.825004427578788" LOG_CI_START="-0.825004427578788" LOG_EFFECT_SIZE="0.0" ORDER="76" O_E="0.0" SE="0.9692233691951198" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.9393939393939394" WEIGHT="10.204081632653061"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9356193549954206" CI_START="0.1663738799787845" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6988636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-015.12" LOG_CI_END="0.4676997424081599" LOG_CI_START="-0.7789148551576638" LOG_EFFECT_SIZE="-0.1556075563747519" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.6246282497106765" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="0.4893015159814796">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9356193549954206" CI_START="0.1663738799787845" EFFECT_SIZE="0.6988636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4676997424081599" LOG_CI_START="-0.7789148551576638" LOG_EFFECT_SIZE="-0.1556075563747519" ORDER="77" O_E="0.0" SE="0.7322675854519449" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.5362158167036215" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.416095274342593" CI_START="0.06023025704556032" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9318181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-015.14" LOG_CI_END="1.158847643847566" LOG_CI_START="-1.2201852833804698" LOG_EFFECT_SIZE="-0.03066881976645196" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.959697688471258" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="0.05053295522112318">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.4160952743426" CI_START="0.060230257045560294" EFFECT_SIZE="0.9318181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1588476438475661" LOG_CI_START="-1.22018528338047" LOG_EFFECT_SIZE="-0.03066881976645196" ORDER="78" O_E="0.0" SE="1.3974557178566656" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="1.9528824833702882" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2408876198620707E-31" CI_END="9.616072823813266" CI_START="0.8126567112044392" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.795454545454545" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-015.20" LOG_CI_END="0.9829977436416608" LOG_CI_START="-0.09009287373524016" LOG_EFFECT_SIZE="0.4464524349532104" METHOD="MH" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.10291970188223812" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="1.6308607663674446">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.616072823813269" CI_START="0.8126567112044394" EFFECT_SIZE="2.7954545454545454" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9829977436416609" LOG_CI_START="-0.09009287373524004" LOG_EFFECT_SIZE="0.4464524349532105" ORDER="79" O_E="0.0" SE="0.6303387405314167" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.39732692781473267" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" NO="16">
<NAME>Oestrogen versus intracervical prostaglandins: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.513135544565797" CI_START="0.6608793267670913" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-016.03" LOG_CI_END="0.17987783325803164" LOG_CI_START="-0.17987783325803167" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.0">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.513135544565797" CI_START="0.6608793267670913" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.17987783325803164" LOG_CI_START="-0.17987783325803167" LOG_EFFECT_SIZE="0.0" ORDER="80" O_E="0.0" SE="0.21132225933080553" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.04465709728867623" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3643561051479853" CI_START="0.8262890368637346" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3977272727272727" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-016.07" LOG_CI_END="0.3737128879679299" LOG_CI_START="-0.08286800938947138" LOG_EFFECT_SIZE="0.1454224392892293" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.21184463655348362" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="1.24850927929971">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3643561051479853" CI_START="0.8262890368637346" EFFECT_SIZE="1.3977272727272727" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.3737128879679299" LOG_CI_START="-0.08286800938947138" LOG_EFFECT_SIZE="0.1454224392892293" ORDER="81" O_E="0.0" SE="0.26819787921963006" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.07193010241790729" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17168801045978077" CI_END="1.2343578974334533" CI_START="0.3887053547832015" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6926770708283313" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-016.11" LOG_CI_END="0.09144110000894747" LOG_CI_START="-0.4103794765110598" LOG_EFFECT_SIZE="-0.15946918825105616" METHOD="MH" NO="11" P_CHI2="0.6786162394572846" P_Q="0.0" P_Z="0.21288201421528463" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="74" WEIGHT="100.0" Z="1.2456797518483052">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2035822249060135" CI_START="0.35946055835062596" EFFECT_SIZE="0.6577540106951871" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.08047576524099329" LOG_CI_START="-0.4443487554351955" LOG_EFFECT_SIZE="-0.18193649509710105" ORDER="82" O_E="0.0" SE="0.3082845213684694" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.09503934611538628" WEIGHT="89.79591836734694"/>
<DICH_DATA CI_END="6.683507312873237" CI_START="0.1496220402233839" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.825004427578788" LOG_CI_START="-0.825004427578788" LOG_EFFECT_SIZE="0.0" ORDER="83" O_E="0.0" SE="0.9692233691951198" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.9393939393939394" WEIGHT="10.204081632653061"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9356193549954206" CI_START="0.1663738799787845" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6988636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-016.12" LOG_CI_END="0.4676997424081599" LOG_CI_START="-0.7789148551576638" LOG_EFFECT_SIZE="-0.1556075563747519" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.6246282497106765" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="0.4893015159814796">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9356193549954206" CI_START="0.1663738799787845" EFFECT_SIZE="0.6988636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4676997424081599" LOG_CI_START="-0.7789148551576638" LOG_EFFECT_SIZE="-0.1556075563747519" ORDER="84" O_E="0.0" SE="0.7322675854519449" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.5362158167036215" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.416095274342593" CI_START="0.06023025704556032" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9318181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-016.14" LOG_CI_END="1.158847643847566" LOG_CI_START="-1.2201852833804698" LOG_EFFECT_SIZE="-0.03066881976645196" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.959697688471258" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="0.05053295522112318">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.4160952743426" CI_START="0.060230257045560294" EFFECT_SIZE="0.9318181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1588476438475661" LOG_CI_START="-1.22018528338047" LOG_EFFECT_SIZE="-0.03066881976645196" ORDER="85" O_E="0.0" SE="1.3974557178566656" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="1.9528824833702882" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2408876198620707E-31" CI_END="9.616072823813266" CI_START="0.8126567112044392" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.795454545454545" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-016.20" LOG_CI_END="0.9829977436416608" LOG_CI_START="-0.09009287373524016" LOG_EFFECT_SIZE="0.4464524349532104" METHOD="MH" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.10291970188223812" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="1.6308607663674446">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.616072823813269" CI_START="0.8126567112044394" EFFECT_SIZE="2.7954545454545454" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9829977436416609" LOG_CI_START="-0.09009287373524004" LOG_EFFECT_SIZE="0.4464524349532105" ORDER="86" O_E="0.0" SE="0.6303387405314167" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.39732692781473267" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" NO="17">
<NAME>Oestrogen versus intracervical prostaglandins: all women, intact membranes, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.513135544565797" CI_START="0.6608793267670913" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="0.17987783325803164" LOG_CI_START="-0.17987783325803167" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.0">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.513135544565797" CI_START="0.6608793267670913" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.17987783325803164" LOG_CI_START="-0.17987783325803167" LOG_EFFECT_SIZE="0.0" ORDER="87" O_E="0.0" SE="0.21132225933080553" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.04465709728867623" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3643561051479853" CI_START="0.8262890368637346" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3977272727272727" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-017.07" LOG_CI_END="0.3737128879679299" LOG_CI_START="-0.08286800938947138" LOG_EFFECT_SIZE="0.1454224392892293" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.21184463655348362" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="1.24850927929971">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3643561051479853" CI_START="0.8262890368637346" EFFECT_SIZE="1.3977272727272727" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.3737128879679299" LOG_CI_START="-0.08286800938947138" LOG_EFFECT_SIZE="0.1454224392892293" ORDER="88" O_E="0.0" SE="0.26819787921963006" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.07193010241790729" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17168801045978077" CI_END="1.2343578974334533" CI_START="0.3887053547832015" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6926770708283313" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-017.11" LOG_CI_END="0.09144110000894747" LOG_CI_START="-0.4103794765110598" LOG_EFFECT_SIZE="-0.15946918825105616" METHOD="MH" NO="11" P_CHI2="0.6786162394572846" P_Q="0.0" P_Z="0.21288201421528463" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="74" WEIGHT="100.0" Z="1.2456797518483052">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2035822249060135" CI_START="0.35946055835062596" EFFECT_SIZE="0.6577540106951871" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.08047576524099329" LOG_CI_START="-0.4443487554351955" LOG_EFFECT_SIZE="-0.18193649509710105" ORDER="89" O_E="0.0" SE="0.3082845213684694" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.09503934611538628" WEIGHT="89.79591836734694"/>
<DICH_DATA CI_END="6.683507312873237" CI_START="0.1496220402233839" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.825004427578788" LOG_CI_START="-0.825004427578788" LOG_EFFECT_SIZE="0.0" ORDER="90" O_E="0.0" SE="0.9692233691951198" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.9393939393939394" WEIGHT="10.204081632653061"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9356193549954206" CI_START="0.1663738799787845" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6988636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-017.12" LOG_CI_END="0.4676997424081599" LOG_CI_START="-0.7789148551576638" LOG_EFFECT_SIZE="-0.1556075563747519" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.6246282497106765" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="0.4893015159814796">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9356193549954206" CI_START="0.1663738799787845" EFFECT_SIZE="0.6988636363636364" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4676997424081599" LOG_CI_START="-0.7789148551576638" LOG_EFFECT_SIZE="-0.1556075563747519" ORDER="91" O_E="0.0" SE="0.7322675854519449" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.5362158167036215" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.416095274342593" CI_START="0.06023025704556032" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9318181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-017.14" LOG_CI_END="1.158847643847566" LOG_CI_START="-1.2201852833804698" LOG_EFFECT_SIZE="-0.03066881976645196" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.959697688471258" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="0.05053295522112318">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.4160952743426" CI_START="0.060230257045560294" EFFECT_SIZE="0.9318181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1588476438475661" LOG_CI_START="-1.22018528338047" LOG_EFFECT_SIZE="-0.03066881976645196" ORDER="92" O_E="0.0" SE="1.3974557178566656" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="1.9528824833702882" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2408876198620707E-31" CI_END="9.616072823813266" CI_START="0.8126567112044392" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.795454545454545" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-017.20" LOG_CI_END="0.9829977436416608" LOG_CI_START="-0.09009287373524016" LOG_EFFECT_SIZE="0.4464524349532104" METHOD="MH" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.10291970188223812" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="41" WEIGHT="100.0" Z="1.6308607663674446">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.616072823813269" CI_START="0.8126567112044394" EFFECT_SIZE="2.7954545454545454" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9829977436416609" LOG_CI_START="-0.09009287373524004" LOG_EFFECT_SIZE="0.4464524349532105" ORDER="93" O_E="0.0" SE="0.6303387405314167" STUDY_ID="STD-Larmon-2002" TOTAL_1="44" TOTAL_2="41" VAR="0.39732692781473267" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" NO="20">
<NAME>Oestrogen versus oxytocin alone: all women</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4197798158281527" CI_START="0.6356619455627172" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-020.03" LOG_CI_END="0.1522209977736508" LOG_CI_START="-0.19677378719595537" LOG_EFFECT_SIZE="-0.022276394711152253" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.8024252238892378" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.25020964908148624">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4197798158281527" CI_START="0.6356619455627172" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.1522209977736508" LOG_CI_START="-0.19677378719595537" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="94" O_E="0.0" SE="0.2050012642431939" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.04202551834130781" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.683507312873237" CI_START="0.1496220402233839" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-020.11" LOG_CI_END="0.825004427578788" LOG_CI_START="-0.825004427578788" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.683507312873237" CI_START="0.1496220402233839" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.825004427578788" LOG_CI_START="-0.825004427578788" LOG_EFFECT_SIZE="0.0" ORDER="95" O_E="0.0" SE="0.9692233691951198" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.9393939393939394" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" NO="21">
<NAME>Oestrogen versus oxytocin alone: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4197798158281527" CI_START="0.6356619455627172" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-021.03" LOG_CI_END="0.1522209977736508" LOG_CI_START="-0.19677378719595537" LOG_EFFECT_SIZE="-0.022276394711152253" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.8024252238892378" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.25020964908148624">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4197798158281527" CI_START="0.6356619455627172" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.1522209977736508" LOG_CI_START="-0.19677378719595537" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="96" O_E="0.0" SE="0.2050012642431939" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.04202551834130781" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.683507312873237" CI_START="0.1496220402233839" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-021.11" LOG_CI_END="0.825004427578788" LOG_CI_START="-0.825004427578788" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.683507312873237" CI_START="0.1496220402233839" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.825004427578788" LOG_CI_START="-0.825004427578788" LOG_EFFECT_SIZE="0.0" ORDER="97" O_E="0.0" SE="0.9692233691951198" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.9393939393939394" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" NO="22">
<NAME>Oestrogen versus oxytocin alone: all women, intact membranes, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4197798158281527" CI_START="0.6356619455627172" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-022.03" LOG_CI_END="0.1522209977736508" LOG_CI_START="-0.19677378719595537" LOG_EFFECT_SIZE="-0.022276394711152253" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.8024252238892378" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.25020964908148624">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4197798158281527" CI_START="0.6356619455627172" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.1522209977736508" LOG_CI_START="-0.19677378719595537" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="98" O_E="0.0" SE="0.2050012642431939" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.04202551834130781" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.683507312873237" CI_START="0.1496220402233839" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-022.11" LOG_CI_END="0.825004427578788" LOG_CI_START="-0.825004427578788" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Intracervical PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.683507312873237" CI_START="0.1496220402233839" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.825004427578788" LOG_CI_START="-0.825004427578788" LOG_EFFECT_SIZE="0.0" ORDER="99" O_E="0.0" SE="0.9692233691951198" STUDY_ID="STD-Magann-1995" TOTAL_1="33" TOTAL_2="33" VAR="0.9393939393939394" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" NO="25">
<NAME>Oestrogen versus extraamniotic prostaglandins: all women</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.20048286508611" CI_START="0.16127776203218527" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.20048286508611" CI_START="0.16127776203218527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" ORDER="100" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.8666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.553341064518706" CI_START="0.06871274407483083" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-025.03" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="101" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-025.04" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="102" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-025.08" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="103" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.402530460804138" CI_START="0.4162278132637267" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-025.11" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="104" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.2" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-025.16" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="105" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" NO="26">
<NAME>Oestrogen versus extraamniotic prostaglandins: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.20048286508611" CI_START="0.16127776203218527" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.20048286508611" CI_START="0.16127776203218527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" ORDER="106" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.8666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.553341064518706" CI_START="0.06871274407483083" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-026.03" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="107" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-026.04" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="108" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-026.08" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="109" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.402530460804138" CI_START="0.4162278132637267" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-026.11" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="110" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.2" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-026.16" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="111" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" NO="27">
<NAME>Oestrogen versus extraamniotic prostaglandins: all primiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.20048286508611" CI_START="0.16127776203218527" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-027.02" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.20048286508611" CI_START="0.16127776203218527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" ORDER="112" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.8666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.553341064518706" CI_START="0.06871274407483083" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-027.03" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="113" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-027.04" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="114" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-027.08" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="115" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.402530460804138" CI_START="0.4162278132637267" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-027.11" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="116" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.2" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-027.16" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="117" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" NO="28">
<NAME>Oestrogen versus extraamniotic prostaglandins: all primiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.20048286508611" CI_START="0.16127776203218527" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-028.02" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.20048286508611" CI_START="0.16127776203218527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7924255116719207" LOG_CI_START="-0.7924255116719207" LOG_EFFECT_SIZE="0.0" ORDER="118" O_E="0.0" SE="0.9309493362512627" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.8666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.553341064518706" CI_START="0.06871274407483083" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-028.03" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="119" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-028.04" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="120" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-028.08" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="121" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.402530460804138" CI_START="0.4162278132637267" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-028.11" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="122" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.2" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-028.16" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.4907574432545426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Extraamniotic PG</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="123" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>